Header Image
Histamine

Sitemap

Histamine

Histamine is a biogenic amine and acts as a neurotransmitter and hormone. It could have a relevant significance in ADHD.
Histamine helps to regulate the release of dopamine. Almost all ADHD medications increase histamine. Histamine often appears to be elevated in ADHD.

The histamine system essentially consists of the histaminergic nerve cells in the tuberomammillary nucleus (TMN), which transmit to almost all brain regions and bind to 4 types of histamine receptors. Activated H1R and H2R have a histamine-increasing effect, while activated presynaptic H3R (autoreceptors) inhibit histamine, acetylcholine and dopamine1
Histamine is strongly linked to the immune system. ADHD, like ASD, is associated with neuroinflammation, among other things.2

Histamine is toxic in high doses. Spoiled fish triggers histamine poisoning within 20 minutes.
Histamine is a strong inflammatory mediator with pleiotropic effects and is involved in the regulation of innate and adaptive immunity.3 ADHD, like ASD, is associated with neuroinflammation, among other things.2

H3 antagonists, which increase histamine as a result, have a beneficial effect on various ADHD symptoms as well as on social symptoms in ASD. ADHD and ASD very often occur comorbidly. Histamine could also play a role in the disorders of the day-night rhythm that are common in ADHD.

An intact histamine system is necessary for the antidepressant effect of SSRIs.4

1. Development of histamine

1.1. Pathway of histamine formation

Conversion of the amino acid L-histidine to histamine by

  • Pyridoxal phosphate-dependent oxidative decarboxylation using the enzyme histidine decarboxylase ( L-histidine decarboxylase, EC 4.1.1.22) or
  • Non-specific aromatic L-amino acid decarboxylase

α-fluoromethyl-histidine suppresses histamine synthesis.5

Histamine is produced by mast cells, basophils, thrombocytes and some neurons, stored in vesicles and released upon stimulation.

1.2. Site of histamine formation in the brain

Only a few nerve cells in the brain produce histamine.6 Synthesis of histamine and storage in vesicles of:7

  • Tuberomammillary nucleus (TMN) in the posterior third of the hypothalamus
    • Neuronal histamine compartment2
      • Contains 60 to 80 % of the brain histamine
    • Main site of the histamine neurons
      • Human: 60,000 to 125,000 histaminergic neurons in the TMN21
      • Rats: 2,30018 to 4,600 histaminergic neurons (in the entire brain)
    • Send via axons to almost all brain regions2, including in
      • Cerebral cortex7, mainly frontal, parietal and occipital lobes2
      • Cerebellum72
      • Posterior pituitary gland7
      • Spinal cord72
      • Hippocampus2
      • Amygdala2
      • VTA2
      • Nucleus accumbens2
      • Substantia nigra2
      • Middle thalamus region2
      • Striatum2
      • Medulla oblongata2
    • TMH cells produce GABA as well as histamine
    • Significantly regulate arousal and alertness
    • There appear to be 5 groups of TMN cells that differ in the expression of the H3 receptor and in the co-expression of GABA, among other things
    • Deactivation of TMN by the GABA agonist muscimol leads to prolonged REM-free sleep; optogenetic activation of a subpopulation of TMN neurons induces wakefulness9
    • The activity of TMN neurons varies depending on the waking state: it is low in the calm waking state, moderate in the active waking state and highest in the alert waking state.10
    • Histamine maintains alertness through direct projections of TMN cells to the thalamus and cortex and indirectly through activation of cholinergic (via H1 and H2 receptors)11, GABAergic1213 and noradrenergic cells (in the locus coeruleus).14
  • Mastocytes (mast cells)
    • Mast cells permanently resident in the brain and mast cells crossing the BBB and traveling through the brain15
    • Contain considerable amounts of histamine from the brain (approx. 20 to 40 %)2
    • Are only found in
      • Thalamus
      • Hypothalamus
      • Dura mater
      • Leptomeninx
      • Choroid plexus
      • In the embryonic histamine system only in16
        • Pia
        • Brain parenchyma
  • Microglia
  • Microvascular endothelial cells

Histamine levels in the brain:2

  • highest mirrors:
    • posterior hypothalamus: above 3.0 pmol/mg initial tissue = in the histaminergic neurons
    • anterior hypothalamus: over 1.5 pmol/mg
  • mean levels in the whole brain
  • lowest levels in cerebellum and medulla oblongata: approx. 0.12 pmol/mg

1.3. Histamine in the body (peripheral)

Synthesis of histamine and storage in vesicles peripherally in7

  • Mast cells
  • Basophils (basophilic granulocytes, a small subgroup of white blood cells (leukocytes))
  • Epidermal cells
  • Gastric mucosa
    • Enterochromaffin-like cells, control the release of gastric acid

Peripheral histamine is mainly involved in3

  • local immune reactions
  • Digestive system

1.4. Histamine and the blood-brain barrier

While histamine cannot cross a healthy blood-brain barrier in adults, histamine is able to cross the blood-brain barrier during development.17

2. Storage of histamine

Storage bound to heparin in vesicles, primarily in

  • Mast cells
  • Basophilic granulocytes
  • Mucous membranes
  • Bronchi
  • Gastrointestinal tract

3. Release of histamine

Release from vesicles peripherally by

  • IgE-mediated allergic reactions of the “immediate type” (type I)
  • Complement factors (e.g. in the case of endotoxin-induced shock)

Release in the CNS must be distinguished from this.

4. Breakdown / reuptake of histamine

Histamine degradation takes place

  • extracellular (esp. food histamine)
    • by means of diamine oxidases (DOA, extracellular; former name: histaminase) and aldehyde oxidases (intracellular) to imidazolylacetic acid.
    • After ribosylation excretion by kidney.
  • intracellular (e.g. in the liver)
    • by histamine methylation (ring methylation by histamine N-methyltransferase)
    • Only a small proportion of histamine degradation
    • In the case of HNMT deficiency, degradation by DAO can increase.

4.1. Dismantling

4.1.1. Degradation in the brain (CNS) primarily due to HNMT

Histamine is inactivated in the brain by the enzyme histamine N-methyltransferase (intracellular) to inactive Nτ-methylhistamine.
HNMT (EC 2.1.1.8) catalyzes the transfer of a methyl group from S-adenosyl-l-methionine (SAM) to histamine, resulting in Nτ-methylhistamine and S-adenosyl-l-homocysteine.18 Nτ-methylhistamine is oxidatively degraded via monoamine oxidases, diamine oxidases (extracellular) and aldehyde oxidases (intracellular) to Nτ-methylimidazolylacetic acid.19

HNMT is found in the human brain in neurons and glial cells in:18

  • Cerebellum (high quantity)
  • frontal cortices (medium quantity)
  • parietal cortices
    • Hippocampus (average amount)
    • Caudate nucleus (medium quantity)
  • temporal cortices
  • occipital cortices

In humans, HNMT shows binding affinity to:18

  • S-Adenosyl-l-methionine (SAM) (Km: 2.0-6.2 µM)
  • Histamine (Km: 13-20 µM)

People without a functioning HNMT show non-syndromic autosomal recessive intellectual disability.2021

HNMT knockout mice showed:22

  • drastically increased histamine levels in the brain, intracellular and extracellular
  • other monoamines in the brain unchanged
  • high aggressiveness due to excessive H2R activation
  • reduced movement activity in home cages
    • probably due to disturbed sleep-wake cycle caused by excessive H1R activation
  • no anxiety-like behavior
  • no depression-like behaviors
  • no memory impairment
  • no motor impairments

Inhibitors of HNMT:18

  • Metoprine
    • Blood-brain-barrier-crossing
    • Antinociception
    • Suppression of energy absorption
    • hyperglycemic effect
    • Improvement of cognitive functions
    • antiepileptic effect
    • Attenuation of methamphetamine-induced behavioral problems
    • Inhibition of dihydrofolate reductase
    • Reduction in cellular folate metabolism, which inhibits cell growth
  • SKF91488
    • has difficulty crossing the blood-brain barrier
  • Amodiaquine
  • Chloroquine
  • Dimaprite
  • Etoprine
  • Quinacrine
  • Tacrine

4.1.2. Degradation in the body primarily by diamine oxidase (DAO, histaminase)

Diamine oxidase (DAO, also known as histaminase) is a homodimeric protein and is encoded by the AOC1 gene. DAO is mainly found in the microvilli of enterocytes.
DAO oxidatively deaminates various amines, among others:18

  • Histamine (Km: 19 µM in the intestine)23
  • Cadaverine (1,5-diaminopentane)
  • Putrescine (Km: 83 µM)
  • N Tau-methylhistamine (N-methylhistamine, 1-methylhistamine) (Km: 97 µM)
  • Spermidine
  • Benzylamine (low)
  • Methylamine (low).
    (Km: Michaelis constant; substrate concentration at which the reaction rate becomes half-maximum)

DAO is mainly expressed in the digestive tract, where it serves to detoxify histamine from food in order to reduce histamine uptake by enterocytes. If DAO is impaired, this results in a higher histamine uptake and thus an increased histamine blood level.18
DAO is also expressed to a lesser extent in the kidneys, placenta24 and lungs. DAO plays little to no role in the brain.25
The optimum pH value for the breakdown of histamine by DAO is 6.4 to 6.6.23
DAO dysfunctions appear to play a role in various diseases.

In the intestine:

  • Histamine intolerance26
  • ischemic bowel syndrome23
  • Mesenteric infarction23
  • Ulcerative colitis23

In the placenta24

  • Gestational diabetes
  • threatened and missed miscarriages
  • trophoblastic disorders.

4.2. Resumption

Astrocytes and endothelial cells play an important role in histamine excretion.2728
The plasma membrane monoamine transporter (PMAT) and the organic cation transporter 3 (OCT3) transport histamine in humans mainly into astrocytes, where it is metabolized by HNMT.29
PMAT and OCT 1 to 3 are polyspecific transporters. They transport various monoamines, including serotonin, dopamine, noradrenaline and histamine.
In contrast to the catecholamines (e.g. DAT, NET) and serotonin (SERT), no high-affinity “uptake 1” transporter has been identified for histamine to date. While uptake 1 transporters generally show strong affinity with Km values below 5 μM, the affinity of uptake 2 transporters is considerably weaker with Km values Km (here: for histamine) of at least 100 μM.29 PMAT and OCT 1 to 3 are therefore low-affinity “uptake 2” transporters.30 Nevertheless, “uptake 2” transporters such as OCR3 contribute to reuptake not only at high concentrations, but at any concentration.

4.2.1. Plasma membrane monoamine transporter (PMAT)

The main description of the PMAT can be found at Dopamine reuptake by the plasma membrane monoamine transporter (PMAT) in the article Dopamine reuptake, dopamine degradation

Discovered in 2004,31 PMAT (encoded by the SLC29A4 gene) is widely distributed in the human brain and appears to be involved in dopamine and serotonin clearance in addition to histamine reuptake.18
PMAT is significantly more involved in histamine reuptake than OCT328 in human astrocytes.29
Whether PMAT reuptakes histamine not only in astrocytes but also presynaptically in histamine neurons remains to be seen.
Km for histamine is at least 100 μM.29
PMAT gene polymorphisms with reduced transport activity for the monoamines serotonin and dopamine as well as the neurotoxin 1-methyl-4-phenylpyridinium (MPP(+)) correlate with Autism Spectrum Disorders (ASD).32
PMAT-KO mice (which therefore have a PMAT deficiency) show neither a strong change in brain histamine levels nor behavioral abnormalities outside of stressful situations.3318

4.2.2. Cation transporter 3, Organic cation transporter 3 (OCT3, SLC22A3)

The main presentation of OCT can be found at Dopamine reuptake by organic cation transporters (OCT) In the article Dopamine reuptake, dopamine degradation

Km of OCT3 for histamine is at least 100 μM.29
Whether OCT3 reuptakes histamine not only in astrocytes but also presynaptically in histamine neurons remains to be seen.29

4.4.3. Cation transporter 2, Organic cation transporter 2 (OCT2, SLC22A2)

In addition to OCT3, the organic cation transporter 2 (OCT2, SLC22A2) also reuptakes histamine, but was not found in human astrocytes,28 but in the human brain, as well as OCT1 (SLC22A1), OCTN1 (SLC22AN1) and OCTN2 (SLC22AN2).34
The human OCT2 transports:29

  • Cations
    • Tetraethylammonium
    • 1-Methyl-4-phenylpyridinium (MPP)
  • Medication
    • Cimetidine (H2R antagonist)
  • Neurotransmitters
    • Histamine
    • Acetylcholine
    • Dopamine
    • Noradrenaline
    • Serotonin
      OCT2 is found in the brain at presynaptic nerve endings in29
  • Cortex
  • Hippocampus
  • Thalamus
  • Hypothalamus
  • dorsal raphe nucleus
  • Locus coeruleus

Km for histamine:29

  • 111 μM (mouse)
  • 0.89 mM (rat)
  • 0.94 mM to 1.3 mM (human).

5. Histamine receptors

5.1. H1 histamine receptor

  • About as often as H2R7
    • Nevertheless functionally significant as H2R
  • Postsynaptic29
    • On non-neuronal target cells (like H2R, unlike H3R)2
  • Low histamine affinity3
  • Is expressed in various cells, including mast cells3
  • Involved in type 1 hypersensitivity reactions3
  • Coupled to7
    • Gq/11 protein1
    • Phospholipase C
      • Promotes inositol trisphosphate (IP3)-dependent Ca2+ release from intracellular Ca2+ stores
      • Is directly involved in the formation of diacylglycerol
        • Activates protein kinase C, which phosphorylates intracellular proteins
    • Activated7
      • AMP kinase
      • Nuclear factor Kappa B
      • Nitric oxide synthases
      • Phospholipase A2 (PLA2)
        • Induces the formation of arachidonic acid
  • Regulatory area
    • Systemic vasodilation (vasodilatation)
    • Reddening of the skin
    • Day-night rhythm
      • Mice without H1 receptors have a disturbed day-night rhythm and are not awakened by H3 antagonists.6
      • Sleep35
    • Vomiting
    • Bronchoconstriction
    • Neurotransmission
    • Possibly antidepressant
    • Possibly anticonvulsant
    • Possibly appetite suppressant
  • Agonists
    • Histamine
    • Histaprodifen (selective agonist)
  • Antagonists
    • All H1 antihistaminergics act as inverse agonists. The term antagonist is therefore misleading.36
    • Loratadine
    • Cetirizine2
    • Fexofenadine
    • Doxylamine
    • Diphenhydramine2
    • Chlorpheniramine (antagonist / inverse agonist)372
    • Mepyramine2
    • Clemastine2
    • Pyrilamine2
    • Triploidin2

5.2. H2 histamine receptor

  • About as often as H1R7
    • Nevertheless functionally less significant than H1R
  • Postsynaptic29
    • On non-neuronal target cells (like H1R, unlike H3R)2
  • Low histamine affinity3
  • Coupled to7
    Gαs1
  • Stimulates adenylyl cyclase7
    • Which increases intracellular cyclic adenosine monophosphate (cAMP)
      • Which activates protein kinase A (PKA) and the transcription factor cAMP response element-binding protein (CREB)
  • Blocks the Ca2+-activated potassium conductivity7
  • Inhibits PLA27
  • Inhibits the release of arachidonic acid7
  • Regulatory area
    • Aggression38
    • Improvement of motor balance and motor coordination via H2 receptors in the cerebellum39
    • Motor activity/exploratory behavior is increased via H2 receptors, not via H1 receptors5
    • Anxiety is primarily increased via H2R and only concomitantly via H1R5
    • Is mainly involved in the cytokine production of Th1 lymphocytes3
    • Gastric acid secretion
    • Reflex tachycardia
  • Agonists
    • Histamine
    • Betazol
    • Amthamine2
    • Dimaprite2
    • Impromidine2
  • Antagonists
    • Cimetidine
    • Famotidine
    • Ranitidine
    • Roxatidine
    • Nizatidine2

5.3. H3 histamine receptor

  • High histamine affinity3
  • Almost exclusively in the brain, only a few in the heart1
    • Frequently in40
      • Especially in dopamine-rich areas such as
        • Dorsal striatum
          • The vast majority of H3Rs are found postsynaptically in the dorsal striatum on the medium-sized spiny output neurons4140
          • 95% (+/- 12%) of all D1-positive and 89% (+/- 12%) of all D2-positive cells in the striatum also contain H3R42
        • Ventral striatum
        • Substantia nigra43
        • Olfactory tubercles
        • But not
          • In the Calleja Islands
          • In VTA
      • PFC
      • Hippocampus
      • Amygdala
      • TMN
  • Short (presynaptic)
    • Is found on histaminergic neurons (presynaptic autoreceptor, less common)729
      • On7
        • Soma
        • Dendrites
        • Axons
    • Not on all histaminergic neurons1
      • Presynaptic = negative feedback to inhibit the synthesis and release of the neurotransmitter produced by the respective neuron
      • Apparently in TMN, Meynert nucleus (nucleus basalis magnocellularis) and cortex, but not in the dorsal and ventral striatum or nucleus accumbens4445
    • Also on terminals of non-histaminergic neurons presynaptically1 (presynaptic heteroreceptor)2
    • In contrast, H1R and H2R are found on non-neuronal target cells2 Therefore, only the H3R is relevant for the effect of histamine as a neurotransmitter
    • Other sources report H3R only as an autoreceptor29
  • Long (postsynaptic)
    • Most H3Rs are located postsynaptically on cells outside the neuronal histaminergic system2
    • Can be found on
      • Other neurons, including glutamate, acetylcholine, GABA (heteroreceptor), large majority72
      • On axons of other nerve cells2 of the basal ganglia7
      • Is found particularly in the dorsal and ventral striatum
  • H3R as well as HNMT, H1R and H2R appear to be frequently expressed in ASA.46
  • Signal paths:7
    • Primarily linked to Gi/o1
      • Inhibits adenylyl cyclase and activates Ca2+ channels
      • Controls histamine synthesis and neurotransmitter release
      • Very high constitutive activity:36
        • Gi/o protein is continuously activated, even if no histamine binds to the receptor
        • Even higher than for the other histamine receptors
        • This means that in addition to agonists and antagonists, there are also inverse agonists1
    • Secondarily also involved in Gq/11 signaling1
      • Activates PLA2
      • Activates Akt/glycogen synthase kinase-3 (GSK3)
      • Activates MAP kinase signaling pathways
    • Inhibition of the Na+/H+ pump
    • Amplification of G-protein-driven inwardly rectifying K+ channels
    • Activation of phospholipase C
    • Controls mitogen-activated protein kinase (MAPK) pathway
    • Controls phosphatidylinositol 3-kinase (PI3K) pathway
  • Regulatory area
    • Neurotransmission
      • H3 antagonists increase the release of histamine (autoregulation) 5
      • H3R agonists
        • Inhibit acetylcholine2
        • Inhibit noradrenaline2
        • Inhibit serotonin2
        • Inhibit dopamine2
      • Glutamate
    • Regulation of the circadian rhythm
    • Involved in the function of the blood-brain barrier3
  • Agonists
    • Histamine
    • Α-Methylhistamine2
    • Immepip2
    • Imetit2
  • Antagonists / inverse agonists
    • Increase the activity of histaminergic neurons in the brain and thus promote arousal and cognition47
    • Probably increase dopamine in the frontal cortex, while agonists decrease dopamine, at least in combination with dopaminergic drugs1
    • Ciproxifan
    • Thioperamide
      • Parkinson’s disease48
      • Increases motor activity / exploratory behavior5
      • Increases anxiety5
    • Pitolisant (antagonist/inverse agonist); Wakix® (pitolisanth hydrochloride)48, selective H3R antagonist/inverse agonist49
      • Narcolepsy, sleep disorders
        • A significantly reduced histamine level in the brain was found in narcolepsy50
      • No effects on:49
        • Striatal dopamine
          • Other than AMP, Modafinil, Solriamfetol
        • Locomotion
          • Even attenuated hyperlocomotion triggered by modafinil or solriamfetol
        • Food intake
    • H3RA 2-1848
      • Epilepsy
    • Clobenpropit (antagonist, inverse agonist)
      • Apparently directly inhibited dopamine reuptake in vitro, as well as somewhat weaker norepinephrine reuptake in striatal and cerebro-cortical synaptosomes51
    • Iodophenpropit
      • Apparently directly inhibited dopamine reuptake in vitro, as well as somewhat weaker norepinephrine reuptake51
    • ABT-288 (selective H3R antagonist)52
    • ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] (selective H3R antagonist)5354
      • Showed full efficacy in the five-time inhibitory avoidance acquisition model in rat pups at 0.1 mg/kg
      • Full efficacy in the social recognition memory model in adult rats at 0.01 mg/kg.
      • Did not stimulate the locomotor system
      • Minor side effects
      • High affinity for rat H3R (pK(i) = 8.9) and human H3R (pK(i) = 9.5)
    • A-349821 (((4’-(3-((R,R)2,5-dimethyl-pyrrolidin-1-yl)-propoxy)-biphenyl-4-yl)-morpholin-4-yl-methanone))55
    • A-304121 [4-(3-((2R)-2-aminopropanoyl-1-piperazinyl)propoxy)phenyl)cyclopropylmethanone]56
      • improved cognitive performance in a five-trial avoidance test for rat pups (10 mg/kg); similar to thioperamide (10 mg/kg), ciproxifan (3 mg/kg) and GT-2331 (1 mg/kg)57
      • social memory in the adult rat significantly improved by 3 and 10 mg/kg57
    • A-317920 [N-((1R)-2-(4-(3-(4-(cyclopropylcarbonyl)phenoxy)propyl)-1-piperazinyl)-1-methyl-2-oxo-ethyl-)-2-furamide]56
      • improved cognitive performance in a five-trial avoidance test for rat pups (3 mg/kg); similar to thioperamide (10 mg/kg), ciproxifan (3 mg/kg) and GT-2331 (1 mg/kg)57
      • significantly improved social memory in the adult rat at 1 and 3 mg/kg57
    • GT-2331 [(1R,2R)-4-(2-(5,5-dimethylhex-1-ynyl)cyclopropyl)imidazole] (1 mg/kg)57
    • Enerisant (competitive antagonist, inverse agonist)47
      • [1-(4-{3-[(2R)-2-methylpyrrolidin-1-yl]propoxy}phenyl)-1H-pyrazol-4-yl](morpholin-4-yl)Methanone monohydrochloride (enerisant hydrochloride)
      • Binds dose-dependently and selectively to the histamine H3 receptor in the frontal cortex
      • Increased extracellular histamine levels in the posterior hypothalamus
      • Increased dopamine and acetylcholine levels in the medial prefrontal cortex
      • Improved cognition
      • Reversed scopolamine-induced cognitive impairment in a social recognition test and a novel object recognition test at 0.03 to 0.3 mg/kg, p.o.
      • Wakefulness-inducing effects at 3 to 10 mg/kg, p.o.
    • ST-713
      • H3 antagonist (Ki = 1.21 nM)
      • D2 antagonist (Ki = 41 nM)
      • D3 antagonist (Ki = 50 nM)
      • Low affinity to other receptors
        • H1 (Ki = 205 nM)
        • H4 (Ki = 210 nM)
        • D1 (Ki = 232 nM)
        • D5 (Ki = 105 nM)
      • Reduced autistic behavior in male BTBR T+tf/J mice.5859
        • ST-713 (3-(2-chloro-10H-phenothiazin-10-yl)-N-methyl-N-(4-(3-(3-(piperidin-1-yl)propoxy)benzyl)propan-1-amine) improved at 2.5, 5 and 10 mg/kg, i.p. dose-dependent
          • social deficits
          • repetitive/compulsive behaviors
          • disturbed states of anxiety
          • but not the hyperactivity of the mice tested
          • 5 mg attenuated the increased protein levels in the hippocampus and cerebellum of
            • NF-κB p65
            • COX-2
            • iNOS
          • Simultaneous administration of an HR agonist or an anticholinergic drug abolished the improvement in social parameters
    • ST-22236061
      • H3R/D2R/D3R receptor antagonist
      • 2.5, 5 and 10 mg/kg, i.p. significantly and dose-dependently attenuated social deficits and disturbed anxiety in BTBR mice
      • Increase of histamine in
        • Cerebellum
        • Striatum
      • Increase in dopamine in
        • PFC
        • Striatum
      • Increase in acetylcholine in
        • PFC
        • Striatum
        • Hippocampus

5.4. H4 histamine receptor

  • High histamine affinity3
  • Is mainly found in1
    • Blood
    • Spleen
    • Lung
    • Liver
    • Intestine62
    • CNS63
  • On non-neuronal cells7
    • Immune cells
      • Mast cells
      • Eosinophils
      • Dendritic cells
    • Microglia (brain)
    • Macrophages2
    • T lymphocytes2
    • Not yet detected on neurons (presumably problem with detection methods)
  • Homology to H3R of approx. 40 %7
  • Signal paths:7
    • Gi/Go-coupled GPCRs
      • Reduces cAMP accumulation
      • Reduces adenylate cyclase activity1
    • Increases Ca2+ mobilization
    • Activates kinases (ERK, PI3K and MAPK)
    • Activates the transcription factor activating protein-1
  • Regulatory area
    • Mast cell chemotaxis
    • Inflammations64
      • H4R stimulation increases histamine and cytokine production3
    • Pain656667
  • Agonists
    • Histamine
    • 4-Methylhistamine
    • Immepip68
    • Clobenopropite (partial agonist)2
    • Clozapine36
  • Antagonists
    • Thioperamide2
    • JNJ-7777120
      • Inhibits proinflammatory microglia and Parkinson’s development in rat model692
    • 2-aminopyrimidines2
    • VUF-60022
    • JNJ-101915842
    • Toreforant (JNJ-38518168)2
    • CZC-137882
    • PF-29884032
    • A-9408942
    • A-9873062
    • JNJ-3922067570

5.5. Histamine receptor heteromers

Receptor heteromers are receptor networks consisting of several receptors of different neurotransmitters.
Histamine receptors form heteromers, among other things, as:71
H3R/Dopamine D2R
H3R/Dopamine D1R
H3R/Adenosine A2A

While D1R are normally coupled to adenylate cyclase via Gs protein, this changes to Gi/o coupling when the D1 dimer dimerizes with the H3 receptor.72
While H3R and D1R act alone against each other, because D1R is coupled to a Gs protein and H3R to a Gi/o protein, they act synchronously as heteromers like H3R. While dopamine normally enhances the activity of the direct pathway via D1R, it inhibits those cells of the direct pathway that are equipped with the D1-H3 heterodimer. This increases the imbalance between the direct pathway (which promotes movement) and the indirect pathway (which inhibits movement). Although these heterodimers have been shown to exist in vivo (Moreno et al., 2011), it is currently unknown how widespread they are and to what extent they contribute to the overall effect of dopamine in the dorsal striatum.

The dorsal striatum has GABAergic projections of medium-sized spiny neurons either to the globus pallidus internus (GPi) (“direct pathway”) or to the globus pallidus externus (GPe) (“indirect pathway”).

Direct path:
The globus pallidus internus normally inhibits the thalamus
Dopamine activates D1R in the striatum. This causes excitation of the downstream neurons.
This excitation inhibits the globus pallidus internus and thus reduces its inhibitory effect on the thalamus.
The thalamus is disinhibited and can activate the motor cortex, which promotes movement.

Indirect path:
Dopamine activates D2R in the striatum. This causes inhibition of the downstream neurons.
This inhibition leads to increased activity in the globus pallidus externus and reduced activity in the subthalamic nucleus.
The increased activity in the globus pallidus externus leads to an increased inhibition of the globus pallidus internus, and the reduced activity in the nucleus subthalamicus leads to a reduced activation of the globus pallidus internus.
This in turn leads to increased inhibition of the thalamus, which inhibits movement.

6. Effect of histamine

Histamine is a potent mediator of many biological reactions, especially inflammatory processes
Histamine is involved in the immune response to foreign pathogens and is produced by basophils and mast cells in the connective tissue around the pathogen.2

  • IgE-dependent release (allergic reaction)
    • after binding of the allergen on the cell surface, histamine is released from the secretory granules of mast cells by cross-linking of IgE antibodies
  • IgE-independent release (allergy-independent)73
    • is regulated by the cyclic nucleotides cAMP and cGMP as “second messengers”
    • Histamine or b-adrenergic stimuli increase the cAMP concentration
      • cAMP inhibits the degranulation of mast cells
    • Histamine release is increased by
      • a-adrenergic and cholinergic influences
        • lowers cAMP
        • promotes histamine release
      • certain inflammatory cytokines
      • Binding of the complement factors C5a, C3a to receptors on mast cells
    • “Non-allergic” histamine liberators can be
      • Medication
      • Foodstuffs
      • chemical stimuli
      • physical stimuli
      • Hypoxia
      • Neuropeptides
      • Enzymes
        • Phospholipase

One of the effects of histamine is2

  • increased permeability of the capillaries. This enables white blood cells and some proteins (e.g. glycoproteins such as immunoglobulins) to penetrate infected tissue in order to fight the pathogens there.
  • Itching as a result of direct stimulation of sensory (pain) nerve endings
  • Activation and migration of endothelial cells, which is essential for angiogenesis.

The human intestinal microbiota can also produce histamine.2

Effect of histamine

  • In the brain7
    • Arousal (arousal)
    • Awakening
      • Activation of TMN neurons promotes alertness
      • During non-REM (Nonrapid Eye Movement) sleep, TMNs fire very little
      • TMN are inactive during REM (Rapid Eye Movement) sleep
    • Maintaining vigilance35
    • Learning and memory7746
      • Histamine appears to play an important role in learning and memory via H1R and H2R
      • HDC-deficient mice show
        • specific changes in task-related learning and memory
        • improved performance in passive avoidance and fear memory
        • gender-specific deficiency or an improvement in the recognition of water labyrinths and new locations
      • Pharmacological blockade of H1R impairs
        • the spatial memory
        • the consolidation of object recognition memory
        • the avoidance memory
      • H2R antagonists block the consolidation of object recognition memory and inhibitory avoidance memory
      • Histamine improves both spatial working and reference memory functions through H1R and H2R in the radial maze task after scopolamine-induced memory deficits
      • Formation or recall of memories requires a certain level of tonic TMN activity.
        • It is possible that strengthening histaminergic signaling in the brain could promote the recovery of seemingly lost memories75
      • H1R or H2R knockout mice show
        • Impairments in object recognition
        • Impairments in the acquisition of spatial memory
        • Improvements in auditory and contextual freezing
      • H1R knockout mice also show
        • severe impairment of memory for temporal sequences
        • Feeding
        • Energy
      • H3R antagonists
        • Show protective effect in various cognitive impairments in Y-maze, object recognition, passive avoidance, radial arm maze and water maze tests
        • Improved detection by the H3R antagonist ciproxifan appears to be at least partially dependent on H1R and H2R
        • Showed memory improvements in Alzheimer’s disease
  • Immune system76
    • Histamine stimulates recruitment of mast cells and basophils at the site of inflammation
      • Reaction to various stimuli such as allergens, pathogens and stress
    • In the innate immune system
      • Intensifies inflammatory reaction
      • Can promote the development of chronic inflammation, apparently via H1R
    • Adaptive immune response
      • Histamine regulates adaptive immune responses at a systemic level (i.e. vascular system, respiratory tract, gut, microbiota, skin and nervous system)
    • Neuroinflammation: depending on the cytokine profile, histamine can have a local proinflammatory or anti-inflammatory effect, also depending on the developmental stage of the CNS2
  • The digestive system76
    • H2R antagonists have a gastroprotective effect
      • Gastritis
      • Gastroesophageal reflux
      • Prevention and treatment of peptic ulcers / bleeding when taking non-steroidal anti-inflammatory drugs (NSAIDs)
  • Social behavior
    • H3R antagonists showed improvements in autistic behaviors
  • Migraine
    • Histamine has a vasodilating effect
    • Migraine attacks are less frequent in the evening, correlating with lower central histaminergic arousal
    • Histamine is involved in migraine pathogenesis via inflammatory pathways
    • Plays a decisive role via an inflammatory pathway
      • H3R agonists are said to have anti-nociceptive and anti-neurogenic anti-inflammatory effects
  • Motivation and stress response77
    • Acute immobilization stress acts via histamine signaling at glutamatergic synapses of D1 receptor-expressing [D1(+)] medium spiny neurons (MSNs) in the nucleus accumbens core
    • Histamine inhibits excitatory gain on D1(+) MSNs via presynaptic H3 receptor-dependent long-term depression, which requires Gβγ-driven Akt-GSK3β signaling
    • Histamine asymmetrically regulates glutamatergic transmission from the PFC and mediodorsal thalamus, with inputs from the PFC cortex undergoing robust long-term depression by histamine
    • Acute immobilization stress attenuates this long-term depression by recruiting endogenous H3 receptor signaling in the nucleus accumbens at glutamatergic synapses on D1(+) MSNs

Histamine can further influence

  • Learning and memory processes78
  • Thermoregulation78
  • Satiety (due to histamine in the brain)79
  • Energy consumption is increased by histamine in the hypothalamus78
  • Glucose uptake and insulin function in the body78
  • Feeding behavior is reduced by histamine in the hypothalamus78, while histamine generally increases arousal for feeding79
  • Improvement of motor balance and motor coordination via H2 receptors in the cerebellum39
  • Increases motor activity/exploratory behavior via H2 receptors, not via H1 receptors5
  • Increases anxiety primarily via H2 receptors and concomitantly via H1 receptors5

7. What influences histamine

The release of histamine in brain neurons is increased by2

  • Stimulation of N-methyl-D-aspartate or N-methyl-D-aspartate (NMDA) receptors
  • Stimulation of μ-opioid receptors
  • Stimulation of dopamine D2 receptors
  • Stimulation of some serotonin receptors.

8. Disorders of the histamine system

Dysfunctions are associated with neuropathological disorders, e.g.19

  • Narcolepsy
    • A significantly reduced brain histamine level was found in narcolepsy50
  • Hallucinations
  • Schizophrenia-like conditions
    An influence of histamine on schizophrenia itself has not yet been proven.80
  • Sleep problems
    • Histamine neurons7
      • Stop firing during the transition from wakefulness to sleep
      • Silence during slow-wave sleep and REM sleep
      • Start firing again after the transition to the waking state
      • Lowest firing in the awake idle state
      • Moderate firing during active wakefulness
      • Maximum firing with high vigilance
    • HDC knockout mice (impaired histamine synthesis) show
      • Sleep fragmentation
      • Increased REM sleep during the light period
      • Significant alertness deficits at the onset of darkness
    • H1 receptor antagonists can help with insomnia80
    • H1R antagonists promote sleep
    • Pathways of histamine on sleep:7
      • The ventrolateral preoptic nucleus (VLPO) is associated with the promotion of sleep
      • Histamine inhibits VLPO neurons indirectly by activating GABAergic interneurons, which in turn disinhibits histaminergic neurons to promote wakefulness
      • Histaminergic axons release paracrine GABA in the neocortex to prevent overactivation by histamine and regulate the level of alertness
      • Histamine can also directly modulate glutamatergic neurons of the thalamus and cause a general excitatory effect in several brain regions
      • Histamine triggers cortical activation through:
        • Activation of cholinergic neurons in the basal forebrain
        • Activation of cholinergic neurons in the mesopontine tegmentum
        • Activation of serotonergic neurons in the dorsal raphe nucleus
        • Direct projections into the cortex
      • The hypocretin system maintains wakefulness largely via histaminergic neurons
      • HCRT neurons and histaminergic neurons
        • Lie side by side in the human hypothalamus
        • Overlap in their projections
        • HCRT neurons directly excite histaminergic neurons via the HCRT receptor 2
      • Histamine possibly regulates HCRT neurons via the H1R
        • The H1R antagonist pyrilamine inhibits HCRT-induced arousal in rats
        • H1R knockout mice show no HCRT-induced increase in alertness
  • Tourette’s (rare)
  • Alzheimer’s and Parkinson’s
    • High histamine levels in the substantia nigra correlate with a reduced number of dopaminergic cells
    • The H1 receptor appears to be affected80
  • Huntington
  • Depression
    • Reduced H1 receptor binding

8.1. Histamine deficiency

  • Tourette syndrome8182
    Histidine decarboxylase knockout (HDC-KO) mice exhibit stereotypic locomotor behaviors that reflect the core phenomenology of Tourette’s.83
  • Rare gene variants of the histamine receptor gene appear to be involved in Tourette’s and Autism Spectrum Disorders.8485
  • A histamine H2 receptor deficiency on parvalbumin-positive neurons in the substantia nigra pars recticulata86
    • Weakens the neuronal activity of these neurons
    • Causes hyperactivity, impulsivity and inattention in mice
    • People with ADHD and mice with DAT deficits showed reduced H2R expression on parvalbumin-positive neurons in the substantia nigra pars recticulata
      • H2R agonists improved their ADHD symptoms

8.2. Histamine excess / histamine intolerance

8.2.1. Development of histamine intolerance

A very good German-language presentation on histamine intolerance can be found at87.

Histamine intolerance is based on an excess of histamine in relation to histamine breakdown.
Histamine obesity can have various causes:

  • Excessive histamine intake (food, fish poisoning)
  • Too little histamine breakdown
    • Mostly diamine oxidase deficiency (peripheral)
    • HNMT deficiency (CNS)
  • Smoking appears to increase histamine levels8889909192
    Histamine moderates reactions to cigarette smoke.93 However, reports that smoking reduces histamine levels94 or leaves them unchanged95 are the exception. However, it is conceivable that smoking increases the reaction to histamine.96979899
  • The cause may also be a systemic mast cell activation disease (MCAD)
    Pathologically altered mast cells (mastocytes, a type of immune cell used to defend against foreign bodies) produce histamine and other messenger substances (mediators). The incidence of MCAD is estimated to be between 1 and 17%.100
    Very good presentation of MCAD at https://www.mastzellaktivierung.info/101
    MCAD works primarily, but not only, by means of histamine.
    • Types of MCAD:
      • Mast cell activation syndrome (MCAS)
      • Systemic mastocytosis (SM) (rare)
      • Mast cell leukemia (MCL) (rare)
    • Mechanisms of action of an MCAD:102
      Percentages indicate the consensus that the mediators mentioned play a role in MCAD.
      • Histamine
        • Headache
        • Low blood pressure
        • Hives (red wheals, urticaria)
          • With or without angioedema (rapidly developing painless swelling)
        • Itching (pruritus)
        • Diarrhea
      • Prostaglandin-D2 (PGD2) (95 %)
        • Mucus secretion
        • Constricted airways (bronchoconstriction)
          • In interaction with thromboxane and PGF2α
        • Vascular instability (dilation of the blood vessels)
        • Sleep inducing
        • Lowering body temperature
        • Possible cause of hereditary hair loss in men together with the steroid hormone dihydrotestosterone (DHT)103
      • PAF2 (platelet-activating factor) (90 %)
        • Abdominal cramps
        • Pulmonary edema
        • Urticaria
        • Bronchoconstriction
        • Hypotension
        • Cardiac arrhythmia
      • Proinflammatory cytokines (80 %)
        • Local inflammation
        • Edema formation
        • Leukocyte migration 80 %
      • LTC4 and LTD4 (80 %)
        • Mucus secretion
        • Edema formation
        • Vascular instability
      • Chemokines (70 %)
        • Acute inflammation
        • Leukocyte recruitment
        • Leukocyte migration
      • Tryptase (65 %)
        • Endothelial activation with subsequent inflammatory reactions
      • Leukotrienes104
        • Allergic reactions
        • Inflammatory reactions

An excessive histamine level causes pseudoallergic symptoms. These vary greatly from person to person, making a diagnosis based on a list of symptoms very difficult.

8.2.2. Frequency of histamine intolerance

The prevalence is 1% of the population. 80% of people with ADHD are middle-aged women, 20% are men.73
More recent studies arrive at higher prevalence values.

8.2.3. Possible symptoms of histamine intolerance

  • Skin
    • Reddening of the skin
    • Hives
    • Eczema
    • Itching[7]
  • Head
    • Headache
    • Feeling of heat
    • Migraine
    • Dizziness
  • Airways
    • Narrowed or runny nose
    • Breathing difficulties
    • Bronchial asthma
    • Sore throat
  • Digestive system
    • Flatulence (bloating)
    • Diarrhea
    • Constipation
    • Nausea/vomiting
    • Abdominal pain
    • Stomach stitches
    • Heartburn
  • Cardiovascular system
    • Changes in blood pressure
      • High blood pressure (hypertension)
      • Low blood pressure (hypotension)
    • Palpitations (tachycardia)
    • Cardiac arrhythmia
  • Urology
    • Menstrual cramps (dysmenorrhea)
    • Cystitis
    • Urethritis
    • Irritation of the mucous membranes of the female genitals
  • Fabric
    • Water retention (edema)
    • Bone marrow edema (BME)
    • Joint pain
  • Energy balance
    • States of exhaustion
    • Seasickness
    • Tiredness
    • Sleep disorders
  • Mental symptoms
    • Confusion
    • Nervousness
    • Depressive moods

8.2.4. Foods that increase histamine

A list of histamine-increasing foods can be found at 105
There are various ways in which food can increase histamine levels.

8.2.4.1. Effects of the histamine increase
8.2.4.1.1. Containing histamine

Foods that contain histamine increase the histamine level.

8.2.4.1.2. Histamine liberators

Some foods cause an increased release of histamine from the salivary vesicles.

8.2.4.1.3. DAO inhibition

Certain substances inhibit the breakdown of histamine by diamine oxidase (DAO).

8.2.4.1.4. DAO mining competitors

Some foods contain substances that also require diamine oxidase (DAO) to break down histamine, which means that less DAO is available to break down histamine.

8.2.4.1.5. Increase in intestinal permeability for histamine

Substances that increase the permeability of the intestinal wall also increase the absorption of histamine.

8.2.4.2. List of triggers for histamine intolerance and MCAD

A very good compilation of MCAD triggers can be found at https://www.mastzellaktivierung.info/106

Foods with high histamine levels are listed in Quade, Bailly, Bartling, Bliesener, Springer: Histamine intolerance.107 This presentation only concerns foods with a high histamine content, not e.g. histamine liberators or DAO degradation competitors.

8.2.5. Treatment of histamine intolerance

The treatment of first choice is a low histamine diet.

A strict low-histamine diet for one month often helps to completely empty the histamine stores. After that, a limited consumption of individual histamine-increasing foods is usually possible. Smoking increases the histamine level considerably and thus undermines the histamine diet.89

In addition, the missing DAO enzyme can be taken 15 to 30 minutes before meals. Taking DAO can only compensate for individual “sins”, but cannot fundamentally avoid a diet.

9. Histamine and ADHD

There is barely any positive knowledge of a correlation between histamine intolerance and ADHD. NCBI / Pubmed did not find a single article under “histamine intolerance adhd”.108

Taking antihistamines (especially first-generation H1R antihistamines) in the first years of life appears to significantly increase the risk of later ADHD. Disorder of REM sleep, which secondarily impairs brain maturation, was cited as a possible cause.109110111
According to another study, former use of antihistamines in people with ADHD increased ADHD symptoms.112

Food additives (here: Sun yellow, carmoisine, tartrazine, ponceau 4R, quinoline yellow, allura red, sodium benzoate) can cause histamine release from circulating basophils. This is not allergic, i.e. not dependent on immunoglobulin E. The increased release of histamine can - in carriers of certain gene variants of the genes that encode histamine-degrading enzymes - increase ADHD symptoms113

A report of 4 individual cases of learning disabled children with ADHD described a very large improvement in ADHD symptoms with antihistamines.114

The H3 histamine receptor is thought to be involved in arousal, control of pituitary hormone secretion, cognitive function, motivation, goal-directed behavior, memory and sleep-wake cycles. However, clinical trials of H3 receptor drugs for ADHD (MK-0249, Bavisant, PF-03654746) have been unsuccessful in phase 2 trials or have been discontinued in phase 2 (betahistine).115

9.1. Histamine often elevated in ADHD

A case study reports an individual case in which methylphenidate caused chronic eosinophilic pneumonia. After discontinuation of MPH and resolution of the pneumonia, it recurred when MPH was taken again, together with reddening of the skin (rush).116 Rush can be a sign of histamine intolerance. Eosinophils are closely linked to the histamine system.
30% of children with ADHD showed elevated histamine urine levels. However, histamine levels did not correlate with the severity of ADHD symptoms.117

A histamine deficiency could also contribute to a dysregulation of the dopamine system.118

9.1.1. Histamine degradation by DAO often reduced in ADHD

A Spanish study found genetically reduced diamine oxidase (DAO) activity in 82.1% of 40 children with ADHD and severely reduced DAO activity in 15.2% (i.e. reduced histamine degradation and consequently (peripherally) increased histamine levels).76 The study is to be extended to 200 children with ADHD and 100 controls. DAO is also called ABP1.
Among 303 children with ADHD, 78.8% were found to have at least one reduced active DAO allele. The severity of ADHD was not influenced by DAO. Certain DAO gene variants had a negative effect on working memory and a partly negative and partly positive effect on IQ.119

9.1.2. Histamine degradation often reduced by HNMT in ADHD

Furthermore, a correlation between ADHD and reduced histamine N-methyltransferase has been described, which also leads to reduced histamine degradation and increased histamine.18
Various HNMT gene polymorphisms are relevant in ADHD and other disorders:

  • Thr105Ile (rs11558538) showed113
    • reduced thermal stability
    • reduced activity of HNMT120, consequently less histamine degradation
    • more adverse effect of food additives on ADHD symptoms in 3- and 8/9-year-old children
    • a reduced risk of Parkinson’s disease121
  • T939C showed
    • more hyperactivity113
    • more adverse effect of food additives on ADHD symptoms in 3- and 8/9-year-old children113

Other gene variants and their influences on HNMT enzyme activity are known, but without reports of an ADHD correlation:

  • G179A showed
    • impaired HNMT enzyme activity
    • mental disability20
  • C314T showed
    • reduced HNMT enzyme activity
    • Km value for histamine increased 1.3-fold (= lower binding affinity)
    • Km value for SAM increased 1.8-fold (= lower binding affinity)
    • rather no correlation with asthma or rhinitis
  • T632C showed
    • impaired HNMT enzyme activity
    • mental disability20
  • A939G (also known as C939T/ rs1050891)113 shows
    • increased HNMT mRNA stability
    • increased HNMT enzyme activity122

9.2. Histamine and dopamine

Animal studies found a correlation between high histamine levels in the substantia nigra and a breakdown of dopaminergic cells, causing reduced dopamine levels.19 So far, no therapeutic benefit of H3 antagonists (which reduce histamine levels and increase dopamine levels) on Alzheimer’s or ADHD has been found.80

Receptor heteromers:7

  • H3R - D1R - Heteromers
    • D1R activation inhibits the production of cAMP instead of stimulating it as usual
    • H3R activation should reduce D13 affinity
  • H3R - D2R - Heteromers
    • only appear to reduce the dopamine affinity of the receptor

The histaminergic system appears to be closely linked to the dopaminergic system and synaptic transmission in the striatum (collection adapted from Hu, Chen (2017), unless another source is cited):7

  • H3 antagonists/inverse agonists increase the release of dopamine
    • In the frontal cortex53 in the presence of dopaminergic drugs or medications1 and ACC123
    • But not in the dorsal or ventral striatum (unchanged there)5344 1 or nucleus accumbens12412570
    • But increased the release of dopamine to methamphetamine in the nucleus accumbens125126
    • H3R appear in the striatum1
      • enhance the inhibition of the indirect pathway induced by dopamine (D2R) (as both are coupled to a Gi/o protein)
        • H3R agonists such as D2R agonists reduce GABA in the striatum, while
      • inhibit the excitation of the direct pathway induced by dopamine (D1R) (since D1R is coupled to a Gs protein and H3R to a Gi/o protein)
        • D1R agonists amplify GABA
        • H3R agonists inhibited D1R agonists127 possibly via postsynaptic effect1
  • Histaminergic neurons can also release dopamine (or GABA) as well
    • The synergistic effects of ciproxifan and halperidol suggest a direct, functional H3/D2 receptor interaction in striatopallidal neurons, so that H3R antagonists could be useful tools to improve the symptomatic treatment of schizophrenia
  • Histamine can selectively activate microglia, leading to increased inflammation characteristic of PD pathology, and damage dopaminergic neurons of the SNc
  • The H3R agonist Immepip alleviates apomorphine-induced turning behavior in 6-hydroxydopamine (6-OHDA)-lesioned rats
  • Simultaneous administration of Immepip or Imetit with L-DOPA alleviates L-DOPA-induced dyskinesia or chorea, but not dystonia
  • Intranigral injection of Immepip increases turning after systemic apomorphine administration in rats
  • The H3R antagonist thioperamide alleviates apomorphine-induced stereotypic behavior in rats with 6-OHDA lesions
  • The H3R antagonist pitolisant alleviates excessive daytime sleepiness in patients with Parkinson’s disease; motor performance remains unchanged.
  • Histamine H2R levels in the striatum are unchanged in patients with Parkinson’s disease. Nevertheless, the H2R antagonists famotidine and ranitidine enhance the antiparkinsonian effect of L-DOPA in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of Parkinson’s disease in macaques and in the 6-OHDA model in rats. H2R antagonists could therefore serve as an aid in the treatment of Parkinson’s disease.
  • The TMN contains a group of dopaminergic neurons that share electrophysiolgical properties with histaminergic neurons
  • H3Rs are expressed on GABAergic input terminals from the substantia nigra reticulata. Stimulation of these receptors reduces GABA release, resulting in increased excitation of dopaminergic cells in the substantia nigra pars compacta
  • Histamine inhibits dopamine release in the mouse striatum via H3R, unlike H3R antagonists
  • H3R regulate the striatum128
  • Most H3Rs in the dorsal and ventral striatum are found postsynaptically on medium-sized spiny output neurons. These cells also contain a large number of D1R and D2R. H3Rs form receptor heterodimers with D1Rs and D2Rs.1
  • Over 85% of D1R- and D2R-expressing MSNs in the dorsal and ventral striatum contain H3R129
  • H3R antagonists (GT-233, 1 mg/kg s.c. and ciproxifan, 3 mg/kg s.c.) significantly and dose-dependently improved the learning performance of SHR pups, as did methylphenidate (1 and 3 mg/kg s.c.) and ABT-418 (agonist at nicotinic acetylcholine receptors, 0.03 mg/kg s.c.). The H3R agonist (R)-alpha-methylhistamine (3 mg/kg s.c.) blocked the cognition-enhancing effect of ciproxifan.130
  • An H3R antagonist131
    • Attenuated the D1R-induced cell death signaling and neuronal degeneration that exists in Huntington’s disease
    • Reduced cognitive and motor learning deficits and loss of D1R-H3R heteromer expression in the Huntington’s disease mouse model
  • Histamine excites dopamine D1R- and D2R-expressing neurons in the striatum equally strongly. This takes place via postsynaptic H1R and H2R.132
  • The H3R agonist α-methylhistamine decreased dopamine release in the ventral (but not in the dorsal) striatum by reducing the activity of striatal cholinergic interneurons133
  • H3R are co-expressed with D1R by striato-nigral medium spiny GABAergic neurons, where they functionally antagonize D1R-mediated responses68
  • H3R agonists modulated in D2R-SPNs (but not in D1R-SPNs)129
    • Akt (serine/threonine PKB) glycogen synthase kinase 3 beta signaling in response to D2R activation via a β-arrestin 2 dependent mechanism
    • The phosphorylation of mitogen- and stress-activated protein kinase 1 and rpS6 (ribosomal protein S6) remained unchanged
  • The selective H3R agonist R-(-)-α-methylhistamine dihydrobromide attenuates movement activity and stereotypical behavior triggered by D2R agonists129
  • H3R-KO fish show reduced dopamine and serotonin levels134
  • Histamine inhibits both cortical and thalamic excitatory projections to MSNs via presynaptic H3Rs
  • Histamine can selectively modulate the dynamics of thalamostriatal synapses to facilitate thalamic inputs
  • Histamine depolarizes both MSN classes via the effect of the H2R
  • Histamine suppresses lateral feedback inhibition between MSN through the H3R or H2R
  • The effect of H2R may be indirectly caused by the activation of H2R in cholinergic interneurons to increase acetylcholine release in the striatum
  • H1R and H2R are co-localized on D1R- and D2R-expressing MSNs and mediate histamine-induced excitation of the two neuron types132
  • Genetic histamine deficiency causes upregulation of dopamine neurotransmission135
  • Increased histaminergic innervation of the entopeduncular nucleus (EPN) in a mouse model of Parkinson’s disease activates parvalbumin neurons (PV) of the EPN that project to the thalamic motor nucleus via hyperpolarization-activated cyclic nucleotide-gated channels (HCN) coupled to postsynaptic H2R. Presynaptic H3R activation in the glutamatergic neurons of the subthalamic nucleus (STN) projecting into the EPN inhibits this. Activation of both receptor types improves the motor dysfunction associated with parkinsonism. Pharmacologic activation of H2R such as genetic upregulation of HCN2 in EPNPV neurons, which reduce neuronal burst firing, improves parkinsonism-associated motor dysfunction independent of changes in neuronal firing rate. Optogenetic inhibition of EPNPV neurons and pharmacological activation or genetic upregulation of H3R in EPN-projecting STNGlu neurons ameliorate parkinsonism-associated motor dysfunction by reducing firing rate rather than altering the firing pattern of EPNPV neurons136
  • In embryos, histamine appears to decrease dopaminergic gene transcription by altering several epigenetic components related to DNA and histone modifications, affecting the development of mDA neurons during development. Histamine showed a long-term effect on the formation of the nigrostriatal and mesolimbic/mesocortical pathways. Histamine caused:137
    • A significant decrease in TH immunoreactivity in the midbrain
    • Changes in dopaminergic neuronal fibers
    • A significantly smaller TH-positive area in the forebrain with whole-body staining
  • HDC-KO mice lack the histamine-producing enzyme histidine decarboxylase (HDC) and therefore also histamine. HDC-KO mice showed:138
    • A pronounced pattern of behavior when exploring a new environment, in particular
    • An increased frequency of sitting up against the wall, jumping and head/body shaking.
    • Reduced dopamine and serotonin levels in the striatum
    • Increased DOPAC dopamine metabolite levels
    • Reduced gene expression of dynorphin and enkephalin
    • Increased striatal dopamine turnover after treatment with the dopamine precursor l-dopa
  • An HNMT inhibitor reduced dopamine and histamine turnover in the striatum, nucleus accumbens and hypothalamus139
  • Dopamine modulation of the basal ganglia appears to be sex-specific:118
    • Histamine in the ventricles of the brain (intracerebroventricular) caused
      • Reduced dopamine in the striatum in male mice
        • Effect was dependent on H2R in the substantia nigra pars compacta (SNc)
        • Knockdown of H2R in GABAergic SNc neurons abolished the effect on
      • Increased dopamine in the striatum in female mice
        • H2R does not influence the effect of histamine on dopamine
        • H3R agonists in the striatum increased dopamine levels in the striatum
        • Effect of histamine on dopamine was modulated by the estrus cycle in females occurred only in proestrus, when estrogen levels are high, and in estrus

9.3. Habenula, ADHD and histamine

Early childhood lesions of the habenula cause behavioral and brain changes similar to those seen in ADHD.140
Histamine H3 receptor antagonists eliminate these symptoms.141

The habenula

  • Transmits limbic information to the midbrain monoamine system
    • Is thereby involved in the regulation of monoamine release in target brain areas such as the striatum, where some of the biological substrates process time perception.
  • Is part of the circadian rhythm network and involved in sleep regulation

ADHD often shows changes in the circadian rhythm, sleep disorders and time perception.

9.4. Histamine in spontaneously hypertensive rat (SHR)

The SHR is the most widely used model animal for ADHD.
Compared to WKY, the SHR:142

  • Histamine
    • increased in
      - Hypothalamus (anterior and posterior) of young and adult SHR
      - Brain stem of young SHR
    • unchanged in
      • Cortex-midbrain
        • but higher in adult WKY and SHR than in young
    • reduced histamine metabolism in:143
      • Hypothalamus
      • Brain stem
      • Chronic L-histidine administration did not affect the hypertension of the SHR
        • different: Chronic administration of L-histidine (100 mg / kg twice daily for 4 weeks) to young SHR prevented the age-related increase in blood pressure and urine norepinephrine levels typical of SHR.144
    • increased histamine release from mast cells145146
      • with reduced nitric oxide release from mast cells145
  • Histidine decarboxylase activity
    • unchanged in
      • Posterior hypothalamus of young and adult SHR
      • Medulla oblongata of young and adult SHR
      • Hypothalamus anterior young SHR
      • Cortex-midbrain and in the brainstem of adult SHR (but higher than in young SHR and WKY)
    • slightly increased
      • Hypothalamus anterior adult SHR
    • increased
      • in the midbrain cortex of young and adult SHR
  • Histamine N-methyltransferase
    • increased
      • in the midbrain cortex of young SHR
    • reduced
      • in the cortex-midbrain of adult SHR
  • H3 receptor147
    • reduced number of amplificates
    • increasing H3 receptor density in the cortex with age as the number of expressed amplicons decreases
    • despite the decrease in the number of expressed amplicons of the H3 receptor, the expression of the larger amplicon (~500 bp) increased

Depletion of histamine in young SHR caused a delay in the age-typical rise in blood pressure.148
Chronic administration of L-histidine (100 mg/kg twice daily for 4 weeks) to young SHR prevented the age-related increase in blood pressure and urine norepinephrine levels typical of SHR.144
Histamine appears to lower blood pressure in SHR by attenuating sympathetic production via the central histamine H3 receptor. The antihypertensive effects of L-histidine correlated with an increase in nitric oxide in the rostral ventrolateral medulla.

H3R antagonists (GT-233, 1 mg/kg s.c. and ciproxifan, 3 mg/kg s.c.) (which have the effect of increasing histamine) significantly and dose-dependently improved the learning performance of SHR pups, as did methylphenidate (1 and 3 mg/kg s.c.) and ABT-418 (agonist at nicotinic acetylcholine receptors, 0.03 mg/kg s.c.). The H3R agonist (R)-alpha-methylhistamine (3 mg/kg s.c.) blocked the cognition-enhancing effects of ciproxifan.130

In SHR, the histamine doses that make the blood-brain barrier more permeable deviate upwards or downwards.149

9.5. Almost all ADHD medications increase histamine

All common ADHD medications increase histamine.150
AMP (lisdexamfetamine) also increased histamine degradation by DAO by strongly upregulating DAO.151
Chronic administration of psychostimulants increases the release of histamine in the striatum.152

Only viloxazine does not appear to increase histamine and has little effect on the histamine system153

More on this under Histamine intolerance / mast cell activation syndrome In the article Choice of medication for ADHD or ADHD with comorbidity

We consider:
Since hypothalamic neuronal histamine (as well as glucagon-like peptide-1 (GLP-1), corticotropin-releasing hormone (CRH)) suppresses food intake154, the histamine increase mediated by ADHD medications, if it also occurs in the hypothalamus, could be a pathway mediating the known effect of appetite reduction by stimulants.

9.6. H2R deficiency can cause ADHD symptoms

A histamine H2 receptor deficiency on parvalbumin-positive neurons in the substantia nigra pars recticulata86

  • Weakens the neuronal activity of these neurons
  • Causes hyperactivity, impulsivity and inattention in mice
  • People with ADHD and mice with DAT deficits showed reduced H2R expression on parvalbumin-positive neurons in the substantia nigra pars recticulata
    • H2R agonists improved their ADHD symptoms

10. Histamine and stress

Histamine is involved in the regulation of the HPA stress axis in stressful situations 15536
Histamine release is a sensitive stress indicator. Immobilization stress and cold reduce histamine156 or histamine turnover.157 Short-term stress (5 minutes) reduces histamine in the midbrain, whereas prolonged stress (30 to 60 minutes) or repeated stress (15 minutes each) does not.158 Exposure of rats to air blasts for 1, 5 and 15 minutes increased histamine in the hypothalamus. The histamine content in the midbrain was increased after 1 and 5 minutes of exposure, while the histamine level in the cerebral cortex only increased after 1 minute of exposure. Prolonged stress (30 minutes) did not affect histamine concentrations in the three brain regions studied, although plasma corticosterone levels remained very significantly (14.5-fold) elevated. Repeated exposure of rats to air bursts lasting 15 minutes led to a significant increase in histamine concentration in the hypothalamus, while histamine in the midbrain and cerebral cortex was not significantly altered.159
In awake rats (12 months), 15 minutes of stress increased histamine in the hypothalamus, but not in the cortex or midbrain.160
Acute stress increased histamine turnover in the diencephalon, nucleus accumbens and striatum. Chronic immobilization stress increased histamine turnover in the nucleus accumbens and the striatum, but not in the diencephalon152
Rats have five different groups of histamine neurons (E1-E5) in the tuberomammillary nucleus (TMN) in the posterior hypothalamus. Immobilization stress, insulin-induced hypoglycemia and foot shock particularly activated the histamine-synthesizing neurons in E4 and E5. Up to 36% of HDC mRNA-expressing cells show c-Fos immunoreactivity in the E5 region. Immobilization stress also activated some neurons of the histaminergic groups E1, E2 and E3. Ether stress, acute hyperosmotic stimulation or the injection of bacterial lipopolysaccharide did not activate the hypothalamic histamine neurons155

TMN neurons can integrate various stress signals (endocrine signals, external stimuli, body perception).154
Stress triggers the neuroendocrine release of ACTH, beta-endorphin and AVP from the pituitary gland via histamine.161

Central administration of CRH increased histamine turnover. CRH-1 receptors are found on the cell body of histamine neurons.154

Histamine injections into the PVN activate the HPA axis via CRH release. During systemic stress, mast cells in the leptomeninges and along the brain capillaries release histamine and CRH
and regulate the permeability of the blood-brain barrier in response to stress.162


  1. Ellenbroek BA (2013): Histamine H₃ receptors, the complex interaction with dopamine and its implications for addiction. Br J Pharmacol. 2013 Sep;170(1):46-57. doi: 10.1111/bph.12221. PMID: 23647606; PMCID: PMC3764848. REVIEW

  2. Szukiewicz D (2024): Histaminergic System Activity in the Central Nervous System: The Role in Neurodevelopmental and Neurodegenerative Disorders. Int J Mol Sci. 2024 Sep 12;25(18):9859. doi: 10.3390/ijms25189859. PMID: 39337347; PMCID: PMC11432521. REVIEW

  3. Blasco-Fontecilla H (2023): Is Histamine and Not Acetylcholine the Missing Link between ADHD and Allergies? Speer Allergic Tension Fatigue Syndrome Re-Visited. J Clin Med. 2023 Aug 17;12(16):5350. doi: 10.3390/jcm12165350. PMID: 37629392; PMCID: PMC10455974.

  4. Munari L, Provensi G, Passani MB, Galeotti N, Cassano T, Benetti F, Corradetti R, Blandina P (2015): Brain Histamine Is Crucial for Selective Serotonin Reuptake Inhibitors’ Behavioral and Neurochemical Effects. Int J Neuropsychopharmacol. 2015 Apr 21;18(10):pyv045. doi: 10.1093/ijnp/pyv045. PMID: 25899065; PMCID: PMC4648163.

  5. Mohsen, Yoshikawa, Miura, Nakamura, Naganuma, Shibuya, Iida, Harada, Okamura, Watanabe, Yanai (2014): Mechanism of the histamine H3 receptor-mediated increase in exploratory locomotor activity and anxiety-like behaviours in mice, Neuropharmacology, Volume 81, 2014, Pages 188-194, ISSN 0028-3908, https://doi.org/10.1016/j.neuropharm.2014.02.003.

  6. Provensi, Costa, Izquierdo, Blandina, Passani (2018): Brain histamine modulates recognition memory: possible implications in major cognitive disorders. Br J Pharmacol. 2018 Aug 21. doi: 10.1111/bph.14478.

  7. Hu W, Chen Z (2017): The roles of histamine and its receptor ligands in central nervous system disorders: An update. Pharmacol Ther. 2017 Jul;175:116-132. doi: 10.1016/j.pharmthera.2017.02.039. PMID: 28223162. REVIEW

  8. Ericson H, Watanabe T, Köhler C (1987): Morphological analysis of the tuberomammillary nucleus in the rat brain: delineation of subgroups with antibody against L-histidine decarboxylase as a marker. J Comp Neurol. 1987 Sep 1;263(1):1-24. doi: 10.1002/cne.902630102. PMID: 2822770.

  9. Fujita, Bonnavion, Wilson, Mickelsen, Bloit, Lecea, Jackson (2017): Hypothalamic Tuberomammillary Nucleus Neurons: Electrophysiological Diversity and Essential Role in Arousal Stability. Journal of Neuroscience 27 September 2017, 37 (39) 9574-9592; DOI: 10.1523/JNEUROSCI.0580-17.2017

  10. Takahashi, Lin, Sakai (2006): Neuronal Activity of Histaminergic Tuberomammillary Neurons During Wake–Sleep States in the Mouse. Journal of Neuroscience 4 October 2006, 26 (40) 10292-10298; DOI: https://doi.org/10.1523/JNEUROSCI.2341-06.2006

  11. Khateb, Fort, Pegna, Jones, Mühlethaler (1995): Cholinergic nucleus basalis neurons are excited by histamine in vitro, Neuroscience, Volume 69, Issue 2, 1995, Pages 495-506, ISSN 0306-4522, https://doi.org/10.1016/0306-4522(95)00264-J

  12. Xu, Michelsen, Wu, Morozova, Panula, Alreja (2004): Histamine innervation and activation of septohippocampal GABAergic neurones: involvement of local ACh release. The Journal of Physiology, 561: 657-670. doi:10.1113/jphysiol.2004.071712

  13. Korotkova, Haas, Brown (2002): Histamine excites GABAergic cells in the rat substantia nigra and ventral tegmental area in vitro, Neuroscience Letters, Volume 320, Issue 3, 2002, Pages 133-136, ISSN 0304-3940, https://doi.org/10.1016/S0304-3940(02)00050-2

  14. Korotkova, Sergeeva, Ponomarenko, Haas (2005): Histamine excites noradrenergic neurons in locus coeruleus in rats. Neuropharmacology, Volume 49, Issue 1, 2005, Pages 129-134, ISSN 0028-3908, https://doi.org/10.1016/j.neuropharm.2005.03.001

  15. Silver R, Silverman AJ, Vitković L, Lederhendler II (1996): Mast cells in the brain: evidence and functional significance. Trends Neurosci. 1996 Jan;19(1):25-31. doi: 10.1016/0166-2236(96)81863-7. PMID: 8787137. REVIEW

  16. Khalil M, Ronda J, Weintraub M, Jain K, Silver R, Silverman AJ (2007): Brain mast cell relationship to neurovasculature during development. Brain Res. 2007 Sep 26;1171:18-29. doi: 10.1016/j.brainres.2007.07.034. PMID: 17764664; PMCID: PMC2049068.

  17. Molina-Hernández A, Díaz NF, Arias-Montaño JA (2012): Histamine in brain development. J Neurochem. 2012 Sep;122(5):872-82. doi: 10.1111/j.1471-4159.2012.07863.x. PMID: 22776024.

  18. Yoshikawa T, Nakamura T, Yanai K (2019): Histamine N-Methyltransferase in the Brain. Int J Mol Sci. 2019 Feb 10;20(3):737. doi: 10.3390/ijms20030737. PMID: 30744146; PMCID: PMC6386932. REVIEW

  19. Shan, Bao, Swaab (2017): Changes in Histidine Decarboxylase, Histamine N-Methyltransferase and Histamine Receptors in Neuropsychiatric Disorders. In: Hattori Y., Seifert R. (eds) Histamine and Histamine Receptors in Health and Disease. Handbook of Experimental Pharmacology, vol 241.

  20. Heidari A, Tongsook C, Najafipour R, Musante L, Vasli N, Garshasbi M, Hu H, Mittal K, McNaughton AJ, Sritharan K, Hudson M, Stehr H, Talebi S, Moradi M, Darvish H, Arshad Rafiq M, Mozhdehipanah H, Rashidinejad A, Samiei S, Ghadami M, Windpassinger C, Gillessen-Kaesbach G, Tzschach A, Ahmed I, Mikhailov A, Stavropoulos DJ, Carter MT, Keshavarz S, Ayub M, Najmabadi H, Liu X, Ropers HH, Macheroux P, Vincent JB (2015): Mutations in the histamine N-methyltransferase gene, HNMT, are associated with nonsyndromic autosomal recessive intellectual disability. Hum Mol Genet. 2015 Oct 15;24(20):5697-710. doi: 10.1093/hmg/ddv286. PMID: 26206890; PMCID: PMC4581600.

  21. Verhoeven WMA, Egger JIM, Janssen PKC, van Haeringen A (2020): Adult male patient with severe intellectual disability caused by a homozygous mutation in the HNMT gene. BMJ Case Rep. 2020 Dec 12;13(12):e235972. doi: 10.1136/bcr-2020-235972. PMID: 33310825; PMCID: PMC7735107.

  22. Yoshikawa T, Nakamura T, Yanai K (2018): [Analysis of brain histamine clearance using genetically engineered mice]. Nihon Yakurigaku Zasshi. 2018;152(1):16-20. Japanese. doi: 10.1254/fpj.152.16. PMID: 29998947.

  23. Biegański T, Kusche J, Lorenz W, Hesterberg R, Stahlknecht CD, Feussner KD (1983): Distribution and properties of human intestinal diamine oxidase and its relevance for the histamine catabolism. Biochim Biophys Acta. 1983 Mar 31;756(2):196-203. doi: 10.1016/0304-4165(83)90092-2. PMID: 6403048.

  24. Maintz L, Schwarzer V, Bieber T, van der Ven K, Novak N (2008): Effects of histamine and diamine oxidase activities on pregnancy: a critical review. Hum Reprod Update. 2008 Sep-Oct;14(5):485-95. doi: 10.1093/humupd/dmn014. PMID: 18499706. REVIEW

  25. McGrath AP, Hilmer KM, Collyer CA, Shepard EM, Elmore BO, Brown DE, Dooley DM, Guss JM (2009): Structure and inhibition of human diamine oxidase. Biochemistry. 2009 Oct 20;48(41):9810-22. doi: 10.1021/bi9014192. PMID: 19764817; PMCID: PMC2791411.

  26. Maintz L, Novak N (2007): Histamine and histamine intolerance. Am J Clin Nutr. 2007 May;85(5):1185-96. doi: 10.1093/ajcn/85.5.1185. PMID: 17490952. REVIEW

  27. Huszti Z (2003): Histamine uptake into non-neuronal brain cells. Inflamm Res. 2003 Apr;52 Suppl 1:S03-6. doi: 10.1007/s000110300028. PMID: 12755385. REVIEW

  28. Yoshikawa T, Naganuma F, Iida T, Nakamura T, Harada R, Mohsen AS, Kasajima A, Sasano H, Yanai K (2013): Molecular mechanism of histamine clearance by primary human astrocytes. Glia. 2013 Jun;61(6):905-16. doi: 10.1002/glia.22484. PMID: 23505051.

  29. Naganuma F, Yoshikawa T (2021): Organic Cation Transporters in Brain Histamine Clearance: Physiological and Psychiatric Implications. Handb Exp Pharmacol. 2021;266:169-185. doi: 10.1007/164_2021_447. PMID: 33641029. (REVIEW)

  30. Gasser PJ, Lowry CA (2018): Organic cation transporter 3: A cellular mechanism underlying rapid, non-genomic glucocorticoid regulation of monoaminergic neurotransmission, physiology, and behavior. Horm Behav. 2018 Aug;104:173-182. doi: 10.1016/j.yhbeh.2018.05.003. PMID: 29738736; PMCID: PMC7137088. REVIEW

  31. Engel K, Zhou M, Wang J (2004): Identification and characterization of a novel monoamine transporter in the human brain. J Biol Chem. 2004 Nov 26;279(48):50042-9. doi: 10.1074/jbc.M407913200. PMID: 15448143.

  32. Adamsen D, Ramaekers V, Ho HT, Britschgi C, Rüfenacht V, Meili D, Bobrowski E, Philippe P, Nava C, Van Maldergem L, Bruggmann R, Walitza S, Wang J, Grünblatt E, Thöny B (2014): Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism. 2014 Aug 13;5:43. doi: 10.1186/2040-2392-5-43. PMID: 25802735; PMCID: PMC4370364.

  33. Duan H, Wang J (2013): Impaired monoamine and organic cation uptake in choroid plexus in mice with targeted disruption of the plasma membrane monoamine transporter (Slc29a4) gene. J Biol Chem. 2013 Feb 1;288(5):3535-44. doi: 10.1074/jbc.M112.436972. PMID: 23255610; PMCID: PMC3561572.

  34. Koepsell H, Lips K, Volk C (2007): Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007 Jul;24(7):1227-51. doi: 10.1007/s11095-007-9254-z. PMID: 17473959. REVIEW

  35. Thakkar (2011): Histamine in the regulation of wakefulness, Sleep Medicine Reviews, Volume 15, Issue 1, 2011, Pages 65-74, ISSN 1087-0792, https://doi.org/10.1016/j.smrv.2010.06.004.

  36. Haas HL, Sergeeva OA, Selbach O (2008): Histamine in the nervous system. Physiol Rev. 2008 Jul;88(3):1183-241. doi: 10.1152/physrev.00043.2007. PMID: 18626069. REVIEW

  37. Márquez-Valadez B, Aquino-Miranda G, Quintero-Romero MO, Papacostas-Quintanilla H, Bueno-Nava A, López-Rubalcava C, Díaz NF, Arias-Montaño JA, Molina-Hernández A (2019): The Systemic Administration of the Histamine H1 Receptor Antagonist/Inverse Agonist Chlorpheniramine to Pregnant Rats Impairs the Development of Nigro-Striatal Dopaminergic Neurons. Front Neurosci. 2019 Apr 16;13:360. doi: 10.3389/fnins.2019.00360. PMID: 31040765; PMCID: PMC6476962.

  38. Naganuma F, Nakamura T, Yoshikawa T, Iida T, Miura Y, Kárpáti A, Matsuzawa T, Yanai A, Mogi A, Mochizuki T, Okamura N, Yanai K (2017): Histamine N-methyltransferase regulates aggression and the sleep-wake cycle. Sci Rep. 2017 Nov 21;7(1):15899. doi: 10.1038/s41598-017-16019-8. PMID: 29162912; PMCID: PMC5698467.

  39. Zhang, Zhuang, Li, Wu, Yung, Zhu, Wang (2016): Selective Modulation of Histaminergic Inputs on Projection Neurons of Cerebellum Rapidly Promotes Motor Coordination via HCN Channels. Mol Neurobiol. 53:1386-401.

  40. Pillot C, Heron A, Cochois V, Tardivel-Lacombe J, Ligneau X, Schwartz JC, Arrang JM (2002): A detailed mapping of the histamine H(3) receptor and its gene transcripts in rat brain. Neuroscience. 2002;114(1):173-93. doi: 10.1016/s0306-4522(02)00135-5. PMID: 12207964.

  41. Ryu JH, Yanai K, Iwata R, Ido T, Watanabe T (1994): Heterogeneous distributions of histamine H3, dopamine D1 and D2 receptors in rat brain. Neuroreport. 1994 Jan 31;5(5):621-4. doi: 10.1097/00001756-199401000-00022. PMID: 8025257.

  42. Moreno E, Hoffmann H, Gonzalez-Sepúlveda M, Navarro G, Casadó V, Cortés A, Mallol J, Vignes M, McCormick PJ, Canela EI, Lluís C, Moratalla R, Ferré S, Ortiz J, Franco R (2011): Dopamine D1-histamine H3 receptor heteromers provide a selective link to MAPK signaling in GABAergic neurons of the direct striatal pathway. J Biol Chem. 2011 Feb 18;286(7):5846-54. doi: 10.1074/jbc.M110.161489. PMID: 21173143; PMCID: PMC3037697.

  43. Anichtchik OV, Peitsaro N, Rinne JO, Kalimo H, Panula P (2001): Distribution and modulation of histamine H(3) receptors in basal ganglia and frontal cortex of healthy controls and patients with Parkinson’s disease. Neurobiol Dis. 2001 Aug;8(4):707-16. doi: 10.1006/nbdi.2001.0413. PMID: 11493035.

  44. Giannoni P, Medhurst AD, Passani MB, Giovannini MG, Ballini C, Corte LD, Blandina P (2010): Regional differential effects of the novel histamine H3 receptor antagonist 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on histamine release in the central nervous system of freely moving rats. J Pharmacol Exp Ther. 2010 Jan;332(1):164-72. doi: 10.1124/jpet.109.158444. PMID: 19815811; PMCID: PMC2802467.

  45. Giannoni P, Passani MB, Nosi D, Chazot PL, Shenton FC, Medhurst AD, Munari L, Blandina P (2009): Heterogeneity of histaminergic neurons in the tuberomammillary nucleus of the rat. Eur J Neurosci. 2009 Jun;29(12):2363-74. doi: 10.1111/j.1460-9568.2009.06765.x. PMID: 19490084.

  46. Wright C, Shin JH, Rajpurohit A, Deep-Soboslay A, Collado-Torres L, Brandon NJ, Hyde TM, Kleinman JE, Jaffe AE, Cross AJ, Weinberger DR (2017): Altered expression of histamine signaling genes in autism spectrum disorder. Transl Psychiatry. 2017 May 9;7(5):e1126. doi: 10.1038/tp.2017.87. PMID: 28485729; PMCID: PMC5534955.

  47. Hino N, Marumo T, Kotani M, Shimazaki T, Kaku-Fukumoto A, Hikichi H, Karasawa JI, Tomishima Y, Komiyama H, Tatsuda E, Nozawa D, Nakamura T, Chaki S (2020): A Novel Potent and Selective Histamine H3 Receptor Antagonist Enerisant: In Vitro Profiles, In Vivo Receptor Occupancy, and Wake-Promoting and Procognitive Effects in Rodents. J Pharmacol Exp Ther. 2020 Nov;375(2):276-285. doi: 10.1124/jpet.120.000185. PMID: 32862143.

  48. Abdulrazzaq YM, Bastaki SMA, Adeghate E (2022): Histamine H3 receptor antagonists - Roles in neurological and endocrine diseases and diabetes mellitus. Biomed Pharmacother. 2022 Jun;150:112947. doi: 10.1016/j.biopha.2022.112947. PMID: 35447544.

  49. Krief S, Berrebi-Bertrand I, Nagmar I, Giret M, Belliard S, Perrin D, Uguen M, Robert P, Lecomte JM, Schwartz JC, Finance O, Ligneau X (2021): Pitolisant, a wake-promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol. Pharmacol Res Perspect. 2021 Oct;9(5):e00855. doi: 10.1002/prp2.855. PMID: 34423920; PMCID: PMC8381683.

  50. Naganuma F, Yoshikawa T (2021): Organic Cation Transporters in Brain Histamine Clearance: Physiological and Psychiatric Implications. Handb Exp Pharmacol. 2021;266:169-185. doi: 10.1007/164_2021_447. PMID: 33641029. REVIEW

  51. Mena-Avila E, Márquez-Gómez R, Aquino-Miranda G, Nieto-Alamilla G, Arias-Montaño JA (2018): Clobenpropit, a histamine H3 receptor antagonist/inverse agonist, inhibits [3H]-dopamine uptake by human neuroblastoma SH-SY5Y cells and rat brain synaptosomes. Pharmacol Rep. 2018 Feb;70(1):146-155. doi: 10.1016/j.pharep.2017.08.007. PMID: 29414147.

  52. Esbenshade TA, Browman KE, Miller TR, Krueger KM, Komater-Roderwald V, Zhang M, Fox GB, Rueter L, Robb HM, Radek RJ, Drescher KU, Fey TA, Bitner RS, Marsh K, Polakowski JS, Zhao C, Cowart MD, Hancock AA, Sullivan JP, Brioni JD (2012): Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther. 2012 Oct;343(1):233-45. doi: 10.1124/jpet.112.194126. PMID: 22815533.

  53. Fox GB, Esbenshade TA, Pan JB, Radek RJ, Krueger KM, Yao BB, Browman KE, Buckley MJ, Ballard ME, Komater VA, Miner H, Zhang M, Faghih R, Rueter LE, Bitner RS, Drescher KU, Wetter J, Marsh K, Lemaire M, Porsolt RD, Bennani YL, Sullivan JP, Cowart MD, Decker MW, Hancock AA (2005): Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther. 2005 Apr;313(1):176-90. doi: 10.1124/jpet.104.078402. PMID: 15608077.

  54. Cowart M, Faghih R, Curtis MP, Gfesser GA, Bennani YL, Black LA, Pan L, Marsh KC, Sullivan JP, Esbenshade TA, Fox GB (2005): Hancock AA. 4-(2-[2-(2(R)-methylpyrrolidin-1-yl)ethyl]benzofuran-5-yl)benzonitrile and related 2-aminoethylbenzofuran H3 receptor antagonists potently enhance cognition and attention. J Med Chem. 2005 Jan 13;48(1):38-55. doi: 10.1021/jm040118g. PMID: 15634000.

  55. Esbenshade TA, Fox GB, Krueger KM, Baranowski JL, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Pan JB, Faghih R, Bennani YL, Williams M, Hancock AA (2004): Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. Biochem Pharmacol. 2004 Sep 1;68(5):933-45. doi: 10.1016/j.bcp.2004.05.048. PMID: 15294456.

  56. Esbenshade TA, Krueger KM, Miller TR, Kang CH, Denny LI, Witte DG, Yao BB, Fox GB, Faghih R, Bennani YL, Williams M, Hancock AA (2003): Two novel and selective nonimidazole histamine H3 receptor antagonists A-304121 and A-317920: I. In vitro pharmacological effects. J Pharmacol Exp Ther. 2003 Jun;305(3):887-96. doi: 10.1124/jpet.102.047183. PMID: 12606603.

  57. Fox GB, Pan JB, Radek RJ, Lewis AM, Bitner RS, Esbenshade TA, Faghih R, Bennani YL, Williams M, Yao BB, Decker MW, Hancock AA (2003): Two novel and selective nonimidazole H3 receptor antagonists A-304121 and A-317920: II. In vivo behavioral and neurophysiological characterization. J Pharmacol Exp Ther. 2003 Jun;305(3):897-908. doi: 10.1124/jpet.102.047241. PMID: 12606600.

  58. Venkatachalam K, Eissa N, Awad MA, Jayaprakash P, Zhong S, Stölting F, Stark H, Sadek B (2021): The histamine H3R and dopamine D2R/D3R antagonist ST-713 ameliorates autism-like behavioral features in BTBR T+tf/J mice by multiple actions. Biomed Pharmacother. 2021 Jun;138:111517. doi: 10.1016/j.biopha.2021.111517. PMID: 33773463.

  59. Eissa N, Awad MA, Thomas SD, Venkatachalam K, Jayaprakash P, Zhong S, Stark H, Sadek B (2022): Simultaneous Antagonism at H3R/D2R/D3R Reduces Autism-like Self-Grooming and Aggressive Behaviors by Mitigating MAPK Activation in Mice. Int J Mol Sci. 2022 Dec 28;24(1):526. doi: 10.3390/ijms24010526. PMID: 36613969; PMCID: PMC9820264.

  60. Eissa N, Venkatachalam K, Jayaprakash P, Falkenstein M, Dubiel M, Frank A, Reiner-Link D, Stark H, Sadek B (2021): The Multi-Targeting Ligand ST-2223 with Histamine H3 Receptor and Dopamine D2/D3 Receptor Antagonist Properties Mitigates Autism-Like Repetitive Behaviors and Brain Oxidative Stress in Mice. Int J Mol Sci. 2021 Feb 16;22(4):1947. doi: 10.3390/ijms22041947. PMID: 33669336; PMCID: PMC7920280.

  61. Eissa N, Venkatachalam K, Jayaprakash P, Yuvaraju P, Falkenstein M, Stark H, Sadek B (2022): Experimental Studies Indicate That ST-2223, the Antagonist of Histamine H3 and Dopamine D2/D3 Receptors, Restores Social Deficits and Neurotransmission Dysregulation in Mouse Model of Autism. Pharmaceuticals (Basel). 2022 Jul 27;15(8):929. doi: 10.3390/ph15080929. PMID: 36015079; PMCID: PMC9414676.

  62. Breunig E, Michel K, Zeller F, Seidl S, Weyhern CW, Schemann M (2007): Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol. 2007 Sep 1;583(Pt 2):731-42. doi: 10.1113/jphysiol.2007.139352. PMID: 17627982; PMCID: PMC2277025.

  63. Connelly WM, Shenton FC, Lethbridge N, Leurs R, Waldvogel HJ, Faull RL, Lees G, Chazot PL (2009): The histamine H4 receptor is functionally expressed on neurons in the mammalian CNS. Br J Pharmacol. 2009 May;157(1):55-63. doi: 10.1111/j.1476-5381.2009.00227.x. PMID: 19413571; PMCID: PMC2697783.

  64. Morgan RK, McAllister B, Cross L, Green DS, Kornfeld H, Center DM, Cruikshank WW (2007): Histamine 4 receptor activation induces recruitment of FoxP3+ T cells and inhibits allergic asthma in a murine model. J Immunol. 2007 Jun 15;178(12):8081-9. doi: 10.4049/jimmunol.178.12.8081. PMID: 17548646.

  65. Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR, Strakhova MI, Vortherms TA, Wakefield BD, Wetter JM, Witte DG, Honore P, Esbenshade TA, Brioni JD, Cowart MD (2008): cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia. J Med Chem. 2008 Nov 27;51(22):7094-8. doi: 10.1021/jm8007618. PMID: 18983139.

  66. Sanna MD, Stark H, Lucarini L, Ghelardini C, Masini E, Galeotti N (2015): Histamine H4 receptor activation alleviates neuropathic pain through differential regulation of ERK, JNK, and P38 MAPK phosphorylation. Pain. 2015 Dec;156(12):2492-2504. doi: 10.1097/j.pain.0000000000000319. PMID: 26270581.

  67. Borgonetti V, Galeotti N (2022): The Histamine H4 Receptor Participates in the Neuropathic Pain-Relieving Activity of the Histamine H3 Receptor Antagonist GSK189254. Int J Mol Sci. 2022 Nov 18;23(22):14314. doi: 10.3390/ijms232214314. PMID: 36430790; PMCID: PMC9692811.

  68. Avila-Luna A, Ríos C, Gálvez-Rosas A, Montes S, Arias-Montaño JA, Bueno-Nava A (2019): Chronic administration of the histamine H3 receptor agonist immepip decreases L-Dopa-induced dyskinesias in 6-hydroxydopamine-lesioned rats. Psychopharmacology (Berl). 2019 Jun;236(6):1937-1948. doi: 10.1007/s00213-019-5182-y. PMID: 30762089.

  69. Zhou P, Homberg JR, Fang Q, Wang J, Li W, Meng X, Shen J, Luan Y, Liao P, Swaab DF, Shan L, Liu C (2019): Histamine-4 receptor antagonist JNJ7777120 inhibits pro-inflammatory microglia and prevents the progression of Parkinson-like pathology and behaviour in a rat model. Brain Behav Immun. 2019 Feb;76:61-73. doi: 10.1016/j.bbi.2018.11.006. PMID: 30408497.

  70. Galici R, Rezvani AH, Aluisio L, Lord B, Levin ED, Fraser I, Boggs J, Welty N, Shoblock JR, Motley ST, Letavic MA, Carruthers NI, Dugovic C, Lovenberg TW, Bonaventure P (2011): JNJ-39220675, a novel selective histamine H3 receptor antagonist, reduces the abuse-related effects of alcohol in rats. Psychopharmacology (Berl). 2011 Apr;214(4):829-41. doi: 10.1007/s00213-010-2092-4. PMID: 21086115.

  71. Łażewska D, Kieć-Kononowicz K. Progress in the development of histamine H3 receptor antagonists/inverse agonists: a patent review (2013-2017). Expert Opin Ther Pat. 2018 Mar;28(3):175-196. doi: 10.1080/13543776.2018.1424135. PMID: 29334795.

  72. Ferrada C, Moreno E, Casadó V, Bongers G, Cortés A, Mallol J, Canela EI, Leurs R, Ferré S, Lluís C, Franco R (2009): Marked changes in signal transduction upon heteromerization of dopamine D1 and histamine H3 receptors. Br J Pharmacol. 2009 May;157(1):64-75. doi: 10.1111/j.1476-5381.2009.00152.x. PMID: 19413572; PMCID: PMC2697789.

  73. Maintz L, Bieber T, Novak N (2006): Die verschiedenen Gesichter der Histaminintoleranz, Konsequenzen für die Praxis / Histamine Intolerance in Clinical Practice, Dtsch Arztebl 2006; 103(51-52): A-3477 / B-3027 / C-2903 (deutsch)

  74. Nomura H, Shimizume R, Ikegaya Y (2022): Histamine: A Key Neuromodulator of Memory Consolidation and Retrieval. Curr Top Behav Neurosci. 2022;59:329-353. doi: 10.1007/7854_2021_253. PMID: 34435342. REVIEW

  75. Costa A, Ducourneau E, Curti L, Masi A, Mannaioni G, Hardt L, Biyong EF, Potier M, Blandina P, Trifilieff P, Provensi G, Ferreira G, Passani MB (2024): Chemogenetic activation or inhibition of histaminergic neurons bidirectionally modulates recognition memory formation and retrieval in male and female mice. Sci Rep. 2024 May 17;14(1):11283. doi: 10.1038/s41598-024-61998-0. PMID: 38760416; PMCID: PMC11101472.

  76. Blasco Fontecilla H, Wang P, Li C, Duelo A, Ruiz-Casares E, Perucho T (2022): PREVALENCIA Y PERFIL CLÍNICO DE LA DEFICIENCIA DE DIAMINO OXIDASA (DAO) EN PACIENTES CON TRASTORNO POR DÉFICIT DE ATENCIÓN E HIPERACTIVIDAD (TDAH); REVISTA DE PSIQUIATRÍA INFANTO-JUVENIL, Volumen 39, Suplemento 1, (2022), Page 104.

  77. Manz KM, Becker JC, Grueter CA, Grueter BA (2020): Histamine H3 Receptor Function Biases Excitatory Gain in the Nucleus Accumbens. Biol Psychiatry. 2021 Mar 15;89(6):588-599. doi: 10.1016/j.biopsych.2020.07.023. PMID: 33012522; PMCID: PMC7865000.

  78. Tabarean (2016): Histamine receptor signaling in energy homeostasis, Neuropharmacology, Volume 106, 2016, Pages 13-19, ISSN 0028-3908, https://doi.org/10.1016/j.neuropharm.2015.04.011.

  79. Provensi, Blandina, Passani (2016): The histaminergic system as a target for the prevention of obesity and metabolic syndrome, Neuropharmacology, Volume 106, 2016, Pages 3-12, ISSN 0028-3908, https://doi.org/10.1016/j.neuropharm.2015.07.002.

  80. Higuchi, Yanai, Okamura, Meguro, Arai, Itoh, Iwata, Ido, Watanabe, Sasaki (2000): Histamine H1 receptors in patients with Alzheimer’s disease assessed by positron emission tomography, Neuroscience, Volume 99, Issue 4, 2000, Pages 721-729, ISSN 0306-4522, https://doi.org/10.1016/S0306-4522(00)00230-X.

  81. Ercan-Sencicek, Stillman, Ghosh, Bilguvar, O’Roak, Mason, Abbott, Gupta, King, Pauls, Tischfield, Heiman, Singer, Gilbert, Hoekstra, Morgan, Loring, Yasuno, Fernandez, Sanders, Louvi, Cho, Mane, Colangelo, Biederer, Lifton, Gunel, State (2010): L-histidine decarboxylase and Tourette’s syndrome. N Engl J Med. 2010 May 20;362(20):1901-8. doi: 10.1056/NEJMoa0907006. . PMID: 20445167; PMCID: PMC2894694.

  82. Karagiannidis, Dehning, Sandor, Tarnok, Rizzo, Wolanczyk, Madruga-Garrido, Hebebrand, Nöthen, Lehmkuhl, Farkas, Nagy, Szymanska, Anastasiou, Stathias, Androutsos, Tsironi, Koumoula, Barta, Zill, Mir, Müller, Barr, Paschou (2013): Support of the histaminergic hypothesis in Tourette syndrome: association of the histamine decarboxylase gene in a large sample of families. J Med Genet. 2013 Nov;50(11):760-4. doi: 10.1136/jmedgenet-2013-101637. PMID: 23825391.

  83. Rapanelli, Frick, Bito, Pittenger (2017): Histamine modulation of the basal ganglia circuitry in the development of pathological grooming. Proc Natl Acad Sci U S A. 2017;114(25):6599-6604. doi:10.1073/pnas.1704547114

  84. Fernandez, Sanders, Yurkiewicz, Ercan-Sencicek, Kim, Fishman, Raubeson, Song, Yasuno, Ho, Bilguvar, Glessner, Chu, Leckman, King, Gilbert, Heiman, Tischfield, Hoekstra, Devlin, Hakonarson, Mane, Günel, State (2012): Rare Copy Number Variants in Tourette Syndrome Disrupt Genes in Histaminergic Pathways and Overlap with Autism, Biological Psychiatry, Volume 71, Issue 5, 2012, Pages 392-402, ISSN 0006-3223, https://doi.org/10.1016/j.biopsych.2011.09.034

  85. Wright, Shin, Rajpurohit, Deep-Soboslay, Collado-Torres, Brandon, Hyde, Kleinman, Jaffe, Cross, Weinberger (2017): Altered expression of histamine signaling genes in autism spectrum disorder. Transl Psychiatry. 2017 May 9;7(5):e1126. doi: 10.1038/tp.2017.87. PMID: 28485729; PMCID: PMC5534955.

  86. An D, You Y, Ma Q, Xu Z, Liu Z, Liao R, Chen H, Wang Y, Wang Y, Dai H, Li H, Jiang L, Chen Z, Hu W (2025): Deficiency of histamine H2 receptors in parvalbumin-positive neurons leads to hyperactivity, impulsivity, and impaired attention. Neuron. 2025 Jan 6:S0896-6273(24)00880-8. doi: 10.1016/j.neuron.2024.12.002. PMID: 39788124.

  87. www.histaminintoleranz.ch. (deutsch)

  88. Bertl, Haririan, Laky, Matejka, Andrukhov, Rausch-Fan (2012): Smoking influences salivary histamine levels in periodontal disease. Oral Dis. 2012 May;18(4):410-6. doi: 10.1111/j.1601-0825.2011.01891.x.

  89. Wilhelm (2017): Anmerkung zu Maintz, Bieber, Novak, in Heft 51–52/2006: Die verschiedenen Gesichter der Histaminintoleranz – Konsequenzen für die Praxis: Tabakrauch ist bedeutende Histaminquelle. Dtsch Arztebl 2007; 104(24): A-1758 / B-1553 / C-1492

  90. Du (1991): [The effects of passive smoking on health].[Article in Chinese] Zhonghua Jie He He Hu Xi Za Zhi. 1991 Apr;14(2):76-8, 126.

  91. Kalenderian, Raju, Roth, Schwartz, Gruber, Janoff (1988): Elevated histamine and tryptase levels in smokers’ bronchoalveolar lavage fluid. Do lung mast cells contribute to smokers’ emphysema? Chest. 1988 Jul;94(1):119-23.

  92. Walter, Walter (1982): Mast cell density in isolated monkey lungs on exposure to cigarette smoke. Thorax. 1982 Sep;37(9):699-702.

  93. Gertner, Bromberger, Traystman, Menkes (1982): Histamine and pulmonary responses to cigarette smoke in periphery of the lung. J Appl Physiol Respir Environ Exerc Physiol. 1982 Sep;53(3):582-8.

  94. Della Rovere, Granata, Familiari, Zirilli, Cimino, Tomaino (2006): Histamine and selenium in lung cancer. Anticancer Res. 2006 Jul-Aug;26(4B):2937-42.

  95. Lewis, Nicholls (1972) Effect of inhaled cigarette smoke on content, release and breakdown of histamine in guinea-pig lung. Life Sci II. 1972 Dec 8;11(23):1167-71.

  96. Daffonchio, Hernandez, Gallico, Omini (1990): Airway hyperreactivity induced by active cigarette smoke exposure in guinea-pigs: possible role of sensory neuropeptides. Pulm Pharmacol. 1990;3(3):161-6.

  97. Keller, Doyle (1976): A mechanism for tobacco smoke-induced allergy. J Allergy Clin Immunol. 1976 Mar;57(3):278-82.

  98. Rijcken, Schouten, Mensinga, Weiss, De Vries, Van der Lende (1993): Factors associated with bronchial responsiveness to histamine in a population sample of adults. Am Rev Respir Dis. 1993 Jun;147(6 Pt 1):1447-53.

  99. Turner, Palmer, Rye, Gibson, Young, Goldblatt, Landau, Le Souëf (2005): Determinants of airway responsiveness to histamine in children. Eur Respir J. 2005 Mar;25(3):462-7.

  100. https://www.mastzellaktivierung.info/de/einleitung_kurzfassung.html#zusammenfassung

  101. https://www.mastzellaktivierung.info/

  102. Valent, Akin, Arock, Brockow, Butterfield, Carter, Castells, Escribano, Hartmann, Lieberman, Nedoszytko, Orfao, Schwartz, Sotlar, Sperr, Triggiani, Valenta, Horny, Metcalfe (2012): Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-25. doi: 10.1159/000328760.

  103. Garza, Liu, Yang, Alagesan, Lawson, Norberg, Loy, Zhao, Blatt, Stanton, Carrasco, Ahluwalia. Fischer. FitzGerald, Cotsarelis (2012): Prostaglandin D2 Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia. Science Translational Medicine 21 Mar 2012: Vol. 4, Issue 126, pp. 126ra34. DOI: 10.1126/scitranslmed.3003122

  104. Mastozytose: Krankheit mit vielen Gesichtern. Pharmazeutische Zeitung Ausgabe 33/2014

  105. https://www.histaminintoleranz.ch/

  106. https://www.mastzellaktivierung.info/de/therapie_ausloesermeiden.html

  107. Quade, Bailly, Bartling, Bliesener, Springer: Histamin-Unverträglichkeit

  108. Abruf 17.03.2022

  109. Fuhrmann, Tesch, Romanos, Abraham, Schmitt (2020): ADHD in school-age children is related to infant exposure to systemic H1-antihistamines. Allergy. 2020 Nov;75(11):2956-2957. doi: 10.1111/all.14411. PMID: 32441335. n = 41.484

  110. Schmitt J, Buske-Kirschbaum A, Tesch F, Trikojat K, Stephan V, Abraham S, Bauer A, Nemat K, Plessow F, Roessner V (2018): Increased attention-deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use. Allergy. 2018 Mar;73(3):615-626. doi: 10.1111/all.13326. PMID: 28975640.

  111. Shan L, Swaab DF (2025): Histamine 2 receptor: Emerging target for the treatment of attention-deficit/hyperactivity disorder. Cell Rep Med. 2025 Mar 18;6(3):102023. doi: 10.1016/j.xcrm.2025.102023. PMID: 40107248; PMCID: PMC11970375. REVIEW

  112. Schmitt, Buske-Kirschbaum, Tesch, Trikojat, Stephan, Abraham, Bauer, Nemat, Plessow, Roessner (2018): Increased attention-deficit/hyperactivity symptoms in atopic dermatitis are associated with history of antihistamine use. Allergy. 2018 Mar;73(3):615-626. doi: 10.1111/all.13326.

  113. Stevenson J, Sonuga-Barke E, McCann D, Grimshaw K, Parker KM, Rose-Zerilli MJ, Holloway JW, Warner JO (2010): The role of histamine degradation gene polymorphisms in moderating the effects of food additives on children’s ADHD symptoms. Am J Psychiatry. 2010 Sep;167(9):1108-15. doi: 10.1176/appi.ajp.2010.09101529. PMID: 20551163. RCT

  114. Levinson (1991): Dramatic favorable responses of children with learning disabilities or dyslexia and attention deficit disorder to antimotion sickness medications: four case reports. Percept Mot Skills. 1991 Dec;73(3 Pt 1):723-38. doi: 10.2466/pms.1991.73.3.723. PMID: 1686492.

  115. Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB (2022): Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol. 2022 Nov 17;13:1066988. doi: 10.3389/fphar.2022.1066988. PMID: 36467081; PMCID: PMC9713849.

  116. Alghamdi D, Jahdali H, Alharbi A, Alshehri A, Alfirm B, Bamefleh H (2024): Methylphenidate causes chronic eosinophilic pneumonia. Ann Thorac Med. 2024 Jan-Mar;19(1):112-115. doi: 10.4103/atm.atm_260_23. PMID: 38444994; PMCID: PMC10911238.

  117. Bruton AM, Robinette LM, Hatsu IE et al. (2024): Urinary Histamine Not Associated with Severity of Symptoms of ADHD and Emotional Dysregulation: A Cross-sectional Secondary Data Analysis from the Micronutrients for ADHD in Youth (MADDY) Study. Adv Neurodev Disord (2024). https://doi.org/10.1007/s41252-024-00432-y

  118. Van Zandt M, Pittenger C (2025): Sex Differences in Histamine Regulation of Striatal Dopamine. J Neurosci. 2025 Jun 11;45(24):e2182242025. doi: 10.1523/JNEUROSCI.2182-24.2025. PMID: 40355265; PMCID: PMC12160404.

  119. Blasco-Fontecilla H, Bella-Fernández M, Wang P, Martin-Moratinos M, Li C (2024): Prevalence and Clinical Picture of Diamine Oxidase Gene Variants in Children and Adolescents with Attention Deficit Hyperactivity Disorder: A Pilot Study. J Clin Med. 2024 Mar 14;13(6):1659. doi: 10.3390/jcm13061659. PMID: 38541885; PMCID: PMC10970994.

  120. Pang YP, Zheng XE, Weinshilboum RM (2001): Theoretical 3D model of histamine N-methyltransferase: insights into the effects of a genetic polymorphism on enzymatic activity and thermal stability. Biochem Biophys Res Commun. 2001 Sep 14;287(1):204-8. doi: 10.1006/bbrc.2001.5570. PMID: 11549275.

  121. Jiménez-Jiménez FJ, Alonso-Navarro H, García-Martín E, Agúndez JAG (2016): Thr105Ile (rs11558538) polymorphism in the histamine N-methyltransferase (HNMT) gene and risk for Parkinson disease: A PRISMA-compliant systematic review and meta-analysis. Medicine (Baltimore). 2016 Jul;95(27):e4147. doi: 10.1097/MD.0000000000004147. PMID: 27399132; PMCID: PMC5058861.

  122. Kim SH, Kang YM, Kim SH, Cho BY, Ye YM, Hur GY, Park HS (2009): Histamine N-methyltransferase 939A>G polymorphism affects mRNA stability in patients with acetylsalicylic acid-intolerant chronic urticaria. Allergy. 2009 Feb;64(2):213-21. doi: 10.1111/j.1398-9995.2008.01795.x. PMID: 19178400.

  123. Medhurst AD, Atkins AR, Beresford IJ, Brackenborough K, Briggs MA, Calver AR, Cilia J, Cluderay JE, Crook B, Davis JB, Davis RK, Davis RP, Dawson LA, Foley AG, Gartlon J, Gonzalez MI, Heslop T, Hirst WD, Jennings C, Jones DN, Lacroix LP, Martyn A, Ociepka S, Ray A, Regan CM, Roberts JC, Schogger J, Southam E, Stean TO, Trail BK, Upton N, Wadsworth G, Wald JA, White T, Witherington J, Woolley ML, Worby A, Wilson DM (2007): GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther. 2007 Jun;321(3):1032-45. doi: 10.1124/jpet.107.120311. PMID: 17327487.

  124. Brioni JD, Esbenshade TA, Garrison TR, Bitner SR, Cowart MD (2011): Discovery of histamine H3 antagonists for the treatment of cognitive disorders and Alzheimer’s disease. J Pharmacol Exp Ther. 2011 Jan;336(1):38-46. doi: 10.1124/jpet.110.166876. PMID: 20864505. REVIEW

  125. Munzar P, Tanda G, Justinova Z, Goldberg SR (2004): Histamine h3 receptor antagonists potentiate methamphetamine self-administration and methamphetamine-induced accumbal dopamine release. Neuropsychopharmacology. 2004 Apr;29(4):705-17. doi: 10.1038/sj.npp.1300380. PMID: 14735131.

  126. Munzar P, Nosál R, Goldberg SR (1998): Potentiation of the discriminative-stimulus effects of methamphetamine by the histamine H3 receptor antagonist thioperamide in rats. Eur J Pharmacol. 1998 Dec 18;363(2-3):93-101. doi: 10.1016/s0014-2999(98)00789-4. PMID: 9881573.

  127. Arias-Montaño JA, Floran B, Garcia M, Aceves J, Young JM (2001): Histamine H(3) receptor-mediated inhibition of depolarization-induced, dopamine D(1) receptor-dependent release of [(3)H]-gamma-aminobutryic acid from rat striatal slices. Br J Pharmacol. 2001 May;133(1):165-71. doi: 10.1038/sj.bjp.0704053. PMID: 11325806; PMCID: PMC1572768.

  128. Rapanelli M (2017): The magnificent two: histamine and the H3 receptor as key modulators of striatal circuitry. Prog Neuropsychopharmacol Biol Psychiatry. 2017 Feb 6;73:36-40. doi: 10.1016/j.pnpbp.2016.10.002. PMID: 27773554. REVIEW

  129. Xu J, Pittenger C (2023): The histamine H3 receptor modulates dopamine D2 receptor-dependent signaling pathways and mouse behaviors. J Biol Chem. 2023 Apr;299(4):104583. doi: 10.1016/j.jbc.2023.104583. PMID: 36871761; PMCID: PMC10139999.

  130. Fox GB, Pan JB, Esbenshade TA, Bennani YL, Black LA, Faghih R, Hancock AA, Decker MW (2002): Effects of histamine H(3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res. 2002 Apr 1;131(1-2):151-61. doi: 10.1016/s0166-4328(01)00379-5. PMID: 11844582.

  131. Moreno-Delgado D, Puigdellívol M, Moreno E, Rodríguez-Ruiz M, Botta J, Gasperini P, Chiarlone A, Howell LA, Scarselli M, Casadó V, Cortés A, Ferré S, Guzmán M, Lluís C, Alberch J, Canela EI, Ginés S, McCormick PJ (2020): Modulation of dopamine D1 receptors via histamine H3 receptors is a novel therapeutic target for Huntington’s disease. Elife. 2020 Jun 9;9:e51093. doi: 10.7554/eLife.51093. PMID: 32513388; PMCID: PMC7282811.

  132. Zhuang QX, Xu HT, Lu XJ, Li B, Yung WH, Wang JJ, Zhu JN (2018): Histamine Excites Striatal Dopamine D1 and D2 Receptor-Expressing Neurons via Postsynaptic H1 and H2 Receptors. Mol Neurobiol. 2018 Oct;55(10):8059-8070. doi: 10.1007/s12035-018-0976-1. PMID: 29498008.

  133. Varaschin RK, Osterstock G, Ducrot C, Leino S, Bourque MJ, Prado MAM, Prado VF, Salminen O, Rannanpää Née Nuutinen S, Trudeau LE (2018): Histamine H3 Receptors Decrease Dopamine Release in the Ventral Striatum by Reducing the Activity of Striatal Cholinergic Interneurons. Neuroscience. 2018 Apr 15;376:188-203. doi: 10.1016/j.neuroscience.2018.01.027. PMID: 29374538.

  134. Puttonen HAJ, Sundvik M, Semenova S, Shirai Y, Chen YC, Panula P (2018): Knockout of histamine receptor H3 alters adaptation to sudden darkness and monoamine levels in the zebrafish. Acta Physiol (Oxf). 2018 Mar;222(3). doi: 10.1111/apha.12981. PMID: 29044927.

  135. Koski SK, Leino S, Panula P, Rannanpää S, Salminen O (2020): Genetic lack of histamine upregulates dopamine neurotransmission and alters rotational behavior but not levodopa-induced dyskinesia in a mouse model of Parkinson’s disease. Neurosci Lett. 2020 Jun 11;729:134932. doi: 10.1016/j.neulet.2020.134932. PMID: 32224226.

  136. Peng JY, Qi ZX, Yan Q, Fan XJ, Shen KL, Huang HW, Lu JH, Wang XQ, Fang XX, Mao L, Ni J, Chen L, Zhuang QX (2023): Ameliorating parkinsonian motor dysfunction by targeting histamine receptors in entopeduncular nucleus-thalamus circuitry. Proc Natl Acad Sci U S A. 2023 Apr 25;120(17):e2216247120. doi: 10.1073/pnas.2216247120. PMID: 37068253; PMCID: PMC10151461.

  137. Vargas-Romero F, González-Barrios R, Guerra-Calderas L, Escobedo-Avila I, Cortés-Pérez D, López-Ornelas A, Rocha L, Soto-Reyes E, Velasco I (2019): Histamine Modulates Midbrain Dopamine Neuron Differentiation Through the Regulation of Epigenetic Marks. Front Cell Neurosci. 2019 May 21;13:215. doi: 10.3389/fncel.2019.00215. PMID: 31178697; PMCID: PMC6536891.

  138. Abdurakhmanova S, Semenova S, Piepponen TP, Panula P (2019): Abnormal behavior, striatal dopamine turnover and opioid peptide gene expression in histamine-deficient mice. Genes Brain Behav. 2019 Nov;18(8):e12595. doi: 10.1111/gbb.12595. PMID: 31216095.

  139. Kitanaka N, Hall FS, Kobori S, Kushihara S, Oyama H, Sasaoka Y, Takechi M, Tanaka KI, Tomita K, Igarashi K, Nishiyama N, Sato T, Uhl GR, Kitanaka J (2021): Metoprine, a histamine N-methyltransferase inhibitor, attenuates methamphetamine-induced hyperlocomotion via activation of histaminergic neurotransmission in mice. Pharmacol Biochem Behav. 2021 Oct;209:173257. doi: 10.1016/j.pbb.2021.173257. PMID: 34418452.

  140. Lee, Goto (2013): Habenula and ADHD: Convergence on time. Neuroscience and biobehavioral reviews (2013), 37(8): 1801-1809

  141. Kim, Goto, Lee (2018): Histamine H3 receptor antagonists ameliorate attention deficit/hyperactivity disorder-like behavioral changes caused by neonatal habenula lesion. Behav Pharmacol. 2018 Feb;29(1):71-78. doi: 10.1097/FBP.0000000000000343.

  142. Prast H, Gujrati V, Walser S, Philippu A (1988): Histamine, histidine decarboxylase and histamine-N-methyltransferase in brain areas of spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol. 1988 Nov;338(5):573-6. doi: 10.1007/BF00179332. PMID: 3244396.

  143. Oishi R, Itoh Y, Nishibori M, Saeki K (1985): Decrease in histamine turnover in the brain of spontaneously hypertensive rats. Brain Res. 1985 Sep 16;343(1):180-3. doi: 10.1016/0006-8993(85)91175-8. PMID: 4041852.

  144. Toba H, Nakamori A, Tanaka Y, Yukiya R, Tatsuoka K, Narutaki M, Tokitaka M, Hariu H, Kobara M, Nakata T (2010): Oral L-histidine exerts antihypertensive effects via central histamine H3 receptors and decreases nitric oxide content in the rostral ventrolateral medulla in spontaneously hypertensive rats. Clin Exp Pharmacol Physiol. 2010 Jan;37(1):62-8. doi: 10.1111/j.1440-1681.2009.05227.x. PMID: 19566844.

  145. Masini E, Mannaioni PF, Pistelli A, Salvemini D, Vane J (1991): Impairment of the L-arginine-nitric oxide pathway in mast cells from spontaneously hypertensive rats. Biochem Biophys Res Commun. 1991 Jun 28;177(3):1178-82. doi: 10.1016/0006-291x(91)90664-s. PMID: 1711845.

  146. Amon EU, Ennis M, Lorenz W, Schnabel M, Schneider C (1990): Histamine release induced by radiographic contrast media. Comparison between pulmonary and peritoneal mast cells derived from normotensive and spontaneously hypertensive rats. Int Arch Allergy Appl Immunol. 1990;92(2):203-8. PMID: 1700769.

  147. Shaw JB, Cai Q, Mtshali C, Myles EL, Washington B (2007): Heterogeneity of histamine H3 receptor genomic expression in the cerebral cortex of spontaneously hypertensive rat. Cell Mol Biol (Noisy-le-grand). 2007 May 15;53(4):45-50. PMID: 17531160.

  148. Prast H, Philippu A (1991): Does brain histamine contribute to the development of hypertension in spontaneously hypertensive rats? Naunyn Schmiedebergs Arch Pharmacol. 1991 Mar;343(3):307-10. doi: 10.1007/BF00251131. PMID: 1865929.

  149. Domer FR, Boertje SB, Bing EG, Reddix I (1983): Histamine- and acetylcholine-induced changes in the permeability of the blood-brain barrier of normotensive and spontaneously hypertensive rats. Neuropharmacology. 1983 May;22(5):615-9. doi: 10.1016/0028-3908(83)90153-3. PMID: 6308494.

  150. Horner, Johnson, Schmidt, Rollema (2007): Methylphenidate and atomoxetine increase histamine release in rat prefrontal cortex. Eur J Pharmacol. 2007 Mar 8;558(1-3):96-7. doi: 10.1016/j.ejphar.2006.11.048. PMID: 17198700.

  151. Tobajas Y, Alemany-Fornés M, Samarra I, Romero-Giménez J, Tintoré M, Del Pino A, Canela N, Del Bas JM, Ortega-Olivé N, de Lecea C, Escoté X (2023): Interaction of Diamine Oxidase with Psychostimulant Drugs for ADHD Management. J Clin Med. 2023 Jul 13;12(14):4666. doi: 10.3390/jcm12144666. PMID: 37510782; PMCID: PMC10380856.}}) MPH neigte dazu, die DAO-Aktivität zu induzieren.{{Tobajas Y, Alemany-Fornés M, Samarra I, Romero-Giménez J, Tintoré M, Del Pino A, Canela N, Del Bas JM, Ortega-Olivé N, de Lecea C, Escoté X (2023): Interaction of Diamine Oxidase with Psychostimulant Drugs for ADHD Management. J Clin Med. 2023 Jul 13;12(14):4666. doi: 10.3390/jcm12144666. PMID: 37510782; PMCID: PMC10380856.

  152. Ito C (2000): The role of brain histamine in acute and chronic stresses. Biomed Pharmacother. 2000 Jun;54(5):263-7. doi: 10.1016/S0753-3322(00)80069-4. PMID: 10917464. REVIEW

  153. Mathew BM, Pellegrini MV (2023): Viloxazine. 2023 Aug 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 35015448.

  154. Gotoh K, Fukagawa K, Fukagawa T, Noguchi H, Kakuma T, Sakata T, Yoshimatsu H (2005): Glucagon-like peptide-1, corticotropin-releasing hormone, and hypothalamic neuronal histamine interact in the leptin-signaling pathway to regulate feeding behavior. FASEB J. 2005 Jul;19(9):1131-3. doi: 10.1096/fj.04-2384fje. PMID: 15894564.

  155. Miklós IH, Kovács KJ (2003): Functional heterogeneity of the responses of histaminergic neuron subpopulations to various stress challenges. Eur J Neurosci. 2003 Dec;18(11):3069-79. doi: 10.1111/j.1460-9568.2003.03033.x. PMID: 14656302.

  156. Taylor KM, Snyder SH (1971): Brain histamine: rapid apparent turnover altered by restraint and cold stress. Science. 1971 Jun 4;172(3987):1037-9. doi: 10.1126/science.172.3987.1037. PMID: 5573952.

  157. Verdière M, Rose C, Schwartz JC (1977): Turnover of cerebral histamine in a stressful situation. Brain Res. 1977 Jun 24;129(1):107-19. doi: 10.1016/0006-8993(77)90973-8. PMID: 871922.

  158. Mazurkiewicz-Kwilecki IM, Taub H (1978): Effect of stress on brain histamine. Pharmacol Biochem Behav. 1978 Oct;9(4):465-8. doi: 10.1016/0091-3057(78)90042-4. PMID: 569863.

  159. Mazurkiewicz-Kwilecki IM (1980): Single and repeated air blast stress and brain histamine. Pharmacol Biochem Behav. 1980 Jan;12(1):35-9. doi: 10.1016/0091-3057(80)90412-8. PMID: 7367460.

  160. Mazurkiewicz-Kwilecki IM, Prell GD (1986): Brain histamine response to stress in 12 month old rats. Life Sci. 1986 Jun 23;38(25):2339-45. doi: 10.1016/0024-3205(86)90641-7. PMID: 2425206.

  161. Kjaer A, Knigge U, Bach FW, Warberg J (1992): Histamine- and stress-induced secretion of ACTH and beta-endorphin: involvement of corticotropin-releasing hormone and vasopressin. Neuroendocrinology. 1992 Sep;56(3):419-28. doi: 10.1159/000126258. PMID: 1331840.

  162. Esposito P, Chandler N, Kandere K, Basu S, Jacobson S, Connolly R, Tutor D, Theoharides TC (2002): Corticotropin-releasing hormone and brain mast cells regulate blood-brain-barrier permeability induced by acute stress. J Pharmacol Exp Ther. 2002 Dec;303(3):1061-6. doi: 10.1124/jpet.102.038497. PMID: 12438528.

Diese Seite wurde am 16.08.2025 zuletzt aktualisiert.